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ABSTRACT 
 
LINDSAY K. SMITH: Glucocorticoid Regulation of microRNA Expression Modulates 
Lymphocyte Apoptosis  
(Under the direction of John A. Cidlowski) 
 
 
Apoptosis of immature thymocytes is a carefully coordinated process that is 
controlled by the actions of pro-apoptotic and anti-apoptotic effectors. Endogenous 
glucocorticoids modulate immune development and function through the induction of 
lymphocyte apoptosis via mechanisms requiring alterations in gene expression. 
Recently, short, non-coding microRNAs have been identified as key regulators of 
lymphocyte function, however, it is unknown whether glucocorticoids regulate non-
coding microRNAs and whether this regulation contributes to lymphocyte apoptosis. 
This dissertation seeks to evaluate the expression and delineate the potential 
regulatory role of microRNAs in glucocorticoid-induced apoptosis of lymphocytes. 
First, this dissertation establishes a “glucocorticoid-induced apoptotic signature” of 
microRNA expression through the demonstration of prevalent repression of 
microRNAs and microRNA bioprocessing machinery. Furthermore, the work 
presented herein delineates the regulatory role of microRNAs in glucocorticoid-
induced apoptosis. Global reduction of microRNA expression via Dicer depletion
ii
 significantly enhanced glucocorticoid-induced apoptosis while the overexpression of 
specific glucocorticoid-repressed microRNAs blunted glucocorticoid induced 
apoptosis, suggesting a role for microRNA processors and specific microRNAs in 
cell life/death decisions.  Finally, studies of primary thymocyte sub-populations 
exhibiting the distinct morphological characteristics of apoptosis identified 
microRNAs uniquely regulated during glucocorticoid-induced and spontaneous 
apoptosis. This analysis also identified the novel induction of microRNAs 223 and 
451 during both apoptotic pathways. This induction occurs under conditions of 
ongoing Dicer depletion. The inhibition of miR-223 activity significantly enhanced 
glucocorticoid-induced apoptosis, suggesting an anti-apoptotic role for this 
microRNA. These studies elucidate the dysregulation of microRNA expression and 
processing during glucocorticoid-induced apoptosis and the Dicer-independent 
induction of apoptotic effector microRNAs in glucocorticoid-induced and 
spontaneously apoptotic thymocyte sub-populations. 
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1.1 MICRORNAS 
MicroRNAs are non-coding, ~21mer, single-stranded post-transcriptional 
regulators of gene expression (1,2). First discovered in C. elegans fifteen years ago, 
highly conserved microRNAs have now been identified and cloned in plants, D. 
melanogaster, rodents, humans and numerous other species (3-11). In plants, 
microRNAs are generally perfectly complementary to their target mRNAs and 
microRNA binding initiates the RNAi pathway, leading to target mRNA cleavage and 
degradation by microRNA-associated endonucleases (12). The majority of animal 
microRNAs however, are imperfectly complementary to their target mRNAs and do 
not initiate RNA cleavage. Instead, the 5’ region of nucleotides 2-7, termed the “seed 
sequence” of the microRNA, binds to a complementary region of the target 3’UTR. 
This imperfect binding hinders target mRNA translation (13-16). MicroRNAs are 
expressed in defined spatiotemporal patterns during development and approximately 
half of annotated microRNAs are expressed in a tissue specific manner (9,17-19). 
To date, microRNAs have been assigned regulatory roles in fundamental biological 
processes, including differentiation, proliferation, embryonic development, and cell 
death (20). Accordingly, the dysregulation of microRNA expression and function is a 
common observation in numerous and diverse human diseases (21). Currently, 
there are over 900 annotated human microRNAs, each with the capacity to regulate 
hundreds of target mRNAs (or approximately 30% of coding genes), establishing 
microRNAs as a large and important class of gene regulatory elements (22-24). 
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Genomic Location Of MicroRNAs 
MicroRNA genes are positioned throughout the genome and are present in 
both coding and non-coding transcripts. The transcripts housing microRNA genes 
are referred to as “host transcripts”. Approximately one half of annotated microRNA 
genes are located within intronic or exonic regions of non-coding host transcripts 
while approximately 40% of microRNA genes are located within intronic regions of 
protein-coding host transcripts (25,26). The majority of these intronic microRNAs are 
co-expressed in the same orientation as their host transcripts, indicating shared 
promoter usage (4). However, approximately 25-33% of intronic microRNAs are not 
strongly co-expressed with their host transcripts or are expressed in the anti-sense 
orientation compared to their host transcripts, indicating that intronic microRNAs can 
also be expressed from independent promoters (27,28). A fraction of microRNA 
genes are located within the 3’UTRs of protein-coding mRNAs. These microRNAs 
are likely generated via read-through transcription of host mRNAs (29,30). 
Additionally, microRNAs are also expressed as polycistronic transcripts bearing 
multiple microRNA hairpins and encoding numerous distinct mature microRNAs 
(3,31). Interestingly, mature microRNAs derived from polycistronic transcripts are 
often differentially expressed due to alternative post-transcriptional processing 
(32,33). Furthermore, clustered microRNAs can arise from the same microRNA 
locus via bidirectional transcription (34). Finally, more than half of annotated 
microRNA genes are located within regions of genomic instability frequently 
translocated in cancer (35). Accordingly, the aberrant expression of microRNAs is a 
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common observation in tumors, suggesting that the dysregulation of microRNA 
expression may play a role in the development of cancer (35). 
Transcription Of MicroRNAs 
 MicroRNAs are transcribed by RNA Polymerase II (Pol II) to generate long 
primary microRNA (pri-miRNA) transcripts (Figure 1.1). The role of Pol II in 
microRNAs transcription was established by the decreased expression of pri-miRNA 
transcripts under conditions of Pol II inhibition and chromatin immunoprecipitation-
demonstrated Pol II-occupancy of a known microRNA promoter (36). Like other Pol 
II generated transcripts, primary microRNA transcripts bear a 5’ 7-methyl guanosine 
cap and a 3’ poly-A tail (29). Furthermore, detailed promoter analysis reveals that 
like mRNA promoters, microRNA promoters contain CpG islands, TATA boxes and 
initiator elements and are subject to histone modifications and transcription factor 
binding (27,28). For example, the transcription of the microRNA 17-92 polycistron is 
positively regulated by the cMyc transcription factor. Members of the microRNA 17-
92 polycistron negatively regulate the expression of the cell cycle regulator E2F1. 
Interestingly, cMyc also positively regulates the expression of E2F1, suggesting that 
a single transcription factor can calibrate cell cycle progression through the 
simultaneous regulation of microRNA and mRNA expression (37). To date, there are 
approximately 243 transcription factor-microRNA regulatory circuits experimentally 
supported in the literature (38). For example, the transcription factor Runx1 induces 
the expression of miR-27a during megakaryopoiesis. MiR-27a in turn negatively 
regulates the expression of Runx-1, thus constituting a feedback microRNA-
transcription factor circuit (39). Alternatively, the cardiac-specific MEF2/MyoD 
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transcription factor is negatively regulated by HDAC4. MEF2/MyoD induces the 
expression of miR-1 which in turn silences HDAC4 expression, allowing for the 
increased expression of MEF2/MyoD and miR-1, constituting a feed-forward 
microRNA-transcription factor circuit (40). Therefore, the prevalent participation of 
microRNAs and transcription factors in complex regulatory circuits allows for tight 
control of gene expression in a developmental and tissue-specific manner.  
 MicroRNA Bioprocessing 
 Primary microRNAs are thousands of nucleotides long and contain a 
characteristic stem-loop structure (29,36). Following transcription, pri-miRNAs are 
processed in the nucleus by the RNase III enzyme Drosha and its co-factor 
DiGeorge Syndrome critical region 8 (DGCR8) (Figure 1.1). Drosha cuts twice, 
cleaving both strands of the stem-loop structure near the base of the stem to yield a 
precursor miRNA (pre-miRNA) hairpin (41). This cleavage creates a staggered cut 
and generates a 5’ phosphate and a 3’ 2-nucleotide overhang characteristic of 
RNase III processing. The second Drosha cleavage occurs a defined distance from 
the first cut, therefore the precise location of Drosha cleavage defines both ends of 
the resulting mature microRNA (41). The correct positioning of Drosha on the pri-
miRNA is crucial for proper microRNA biogenesis and this positioning requires co-
factor activity. Drosha exists in a ~500-650 kD protein complex, known as the 
Microprocessor, with its cofactor DGCR8 (also known as Pasha) (42-44). 
DGCR8/Pasha binds directly to the RNase III domain of Drosha and contains two 
double-stranded RNA binding domains (dsRBD) (44). These domains are critical for 
pri-miRNA recognition and facilitate Microprocessor binding. The cooperative activity 
5
of both Drosha and DGCR8 are required for proper microRNA processing and si-
RNA mediated depletion of either member of the Microprocessor complex results in 
the reduced expression of both pre-miRNAs and mature microRNAs (42-45).  
 In addition to DGCR8, there is increasing evidence that the Microprocessor 
complex contains additional regulatory factors. Immunoprecipitation-mass 
spectrometry analysis identified the DEAD-box RNA helicases p68 and p72 as 
members of the Microprocessor complex (43,46). Depletion of either p68 or p72 
reduced the expression of both pre-miRNAs and mature microRNAs. Furthermore, 
this depletion reduced Drosha binding to pri-miRNAs, suggesting that p68 and p72 
stabilize Drosha binding to pri-miRNAs (47). Additionally, immunoprecipitation 
studies have also detected p53 in association with Drosha and p68 and the 
exogenous addition of recombinant p53 enhanced Drosha processing (48). Finally, 
the KH-type splicing regulatory protein (KSRP), an RNA binding protein, has also 
been identified in the Microprocessor complex and depletion of KSRP hindered the 
processing activity of Drosha (49). How these accessory proteins enhance Drosha 
processing is unclear, however they likely serve to enhance the recruitment of the 
Microprocessor to the pri-miRNA or increase the enzymatic cleavage activity of the 
Microprocessor complex. Alternatively, inhibition of Drosha processing by accessory 
proteins has also been reported. For example, the dsRNA-binding protein (dsRBP) 
lin-28 occupies the loop region of let-7 family members, hindering Drosha 
occupation and processing of let-7 family members (50-52). Additionally, a recent 
study found that ligand-bound estrogen receptor alpha directly interacts with Drosha, 
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resulting in the attenuation of pri-miRNA processing and indicating that nuclear 
hormone receptors can also participate in the Microprocessor complex (53).  
Little is known about the mechanisms regulating Drosha and DGCR8 
expression. However, there is evidence to suggest that the dysregulation of these 
Microprocessor proteins may contribute to pathogenesis. For example, Drosha 
expression is upregulated in cervical, esophageal, and epithelial skin cancers (54-
56). However, in cervical cancers, Drosha upregulation did not significantly alter 
mature microRNA expression (55). The gene encoding DGCR8 is located at 
ch22q11, a fragile site whose deletion results in DiGeorge Syndrome (57). A mouse 
model of DiGeorge Syndrome exhibited a modest decrease in mature microRNA 
expression (58). However, it is curious that in most cases, the dysregulation of these 
two key microRNA processing proteins did not significantly alter mature microRNA 
expression. This may be due, in part, to the recent discovery of a complex 
Drosha/DGCR8 regulatory feedback loop. Drosha negatively regulates the 
expression of DGCR8 through the cleavage of DGCR8 mRNA and DGCR8 in turn 
positively regulates Drosha via protein stabilization, thus resulting in homeostatic 
control of Microprocessor expression and the stabilization of microRNA biosynthesis 
(59).  
Following Microprocessor-mediated cleavage, pre-miRNA hairpins are 
exported from the nucleus in an Exportin-5/Ran-GTP dependent manner (60) 
(Figure 1.1). Exportin-5 is a member of the karyopherin family of nucleocytoplasmic 
transporters that cooperates with the small GTPase Ran to facilitate nuclear export 
(60-62). In the nucleus, the Exportin-5/Ran-GTP dimer binds specifically to small (at 
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least 16bp long) double stranded RNAs bearing a 3’ overhang, which is exactly the 
structure of Microprocessor-generated pre-miRNAs (62,63). Once bound, the pre-
miRNA/Exportin-5/Ran-GTP heterotrimer is exported to the cytoplasm where GTP 
hydrolysis liberates the pre-miRNA from the Exportin-5 complex, releasing it into the 
cytoplasm (61,62). Depletion of Exportin-5 expression led to a predicted reduction in 
cytoplasmic pre-miRNA levels and, surprisingly, the reduced nuclear accumulation 
of pre-miRNAs, suggesting that Exportin-5 may mediate the stabilization of nuclear 
pre-miRNAs prior to export (60). Furthermore, the overexpression of Exportin-5 
resulted in the increased expression of mature, cytoplasmic microRNAs, indicating 
that the expression level of Exportin-5 determines the rate of microRNA 
bioprocessing (64).  
In the cytoplasm, pre-microRNAs are further processed by the RNase III 
enzyme, Dicer (65,66) (Figure 1.1). Dicer cleaves the pre-miRNA adjacent to the 
terminal loop to generate a ~21nt double stranded microRNA duplex bearing a 2-nt 
3’ overhang characteristic of RNase III processing (67). In mammals, Dicer is a 
multidomain protein consisting of the DExD/H-box helicase DUF283, a dsRBD, two 
RNase III domains, and a PAZ domain (68). Recent studies have found that the 
DUF283 helicase domain facilitates the cleavage of hairpins containing 
thermodynamically unstable regions (69). The PAZ domain specifically recognizes 
and binds with high affinity the ends of dsRNAs bearing a 2-nt 3’ overhang (i.e.: the 
products of Microprocessor cleavage) (70,71). The dsRBD then binds within the pre-
miRNA stem and determines the distance of cleavage from the PAZ-bound base 
(~22nt) (72). Cleavage is then mediated by the two RNase III domains, resulting in 
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the cleavage of the terminal loop structure and the generation of the ~22nt 
microRNA duplex (73).  
Dicer activity is essential for the generation of mature microRNAs. Therefore, 
Dicer is highly conserved and Dicer homologs have been identified in all higher 
eukaryotes expressing mature microRNAs (74). Dicer is also a member of a multi-
protein complex with the double-stranded RNA-binding proteins TAR RNA-binding 
protein (TRBP) and protein kinase R-activating protein (PACT) (75-77). Depletion of 
either of these accessory proteins resulted in decreased Dicer stability and 
expression, indicating that these proteins are essential for the stabilization of Dicer 
expression (77,78).  
Like the Microprocessor proteins, aberrant expression of Dicer is also 
correlated with disease development. Dicer expression is upregulated in prostate 
cancer, cultured lymphoma cell lines, and lung adenocarcinoma (79-82) while Dicer 
expression is reduced in ovarian cancer and non-small cell lung cancers (83,84). 
The mechanisms governing Dicer expression and activity are poorly understood. It 
has been demonstrated that, like Drosha, the dsRBP lin-28 can inhibit Dicer 
processing of Let-7 family members (52,85). This inhibition occurs through 
competitive binding of Let-7 family members or through lin-28 promoted 3’-
uridylation of pre-let-7, thus inhibiting Dicer processing (52,86). Interestingly, Dicer 
expression is negatively regulated post-transcriptionally via let-7 family members, 
demonstrating a novel negative feedback loop which impacts the biogenesis of all 
mature microRNAs (87,88). Dicer expression and activity can also be positively 
regulated post-translationally via the proteolytic removal or TRBP-promoted 
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rearrangement of the N-terminal Dicer helicase domain, suggesting that this domain 
serves an auto-inhibitory function (89-91). Finally, computational studies of the Dicer 
protein sequence predict numerous conserved phosphorylation sites, suggesting 
that Dicer function may be modified post-translationally via phosphorylation (92).    
During microRNA biogenesis, the Dicer complex is also associated with 
Argonaute (Ago) proteins (93). Ago family members are approximately 100 kD 
proteins containing both PAZ and PIWI domains (94). The PAZ domain is 
responsible for the direct binding of Ago proteins to single stranded RNAs, allowing 
for the retention of the mature microRNA in the RNA-Induced Silencing Complex 
(RISC) (95-97). Argonaute proteins are the core components of the RISC and are 
required for proper microRNA function. Of the eight Argonaute proteins present in 
the human genome, Argonaute-2 (Ago-2) has been identified in association with 
Dicer in-vivo and is the only Ago protein possessing inherent RNA cleavage activity 
(76,98). Therefore, it is widely accepted that Ago-2 plays a crucial role in microRNA-
mediated post-transcriptional regulation of gene expression. Ectopic overexpression 
of Ago-2 resulted in a significant increase in mature microRNA expression while 
lymphoid cells from Ago-2 knockout mice exhibited a global reduction in mature 
microRNA expression, suggesting that in addition to mediating microRNA activity, 
Ago-2 also serves to stabilize microRNA expression (99,100).  
Following pre-microRNA cleavage, the Dicer-associated proteins TRBP and 
PACT facilitate loading of the microRNA duplex into the RISC Loading Complex 
(76). Within the RISC Loading Complex, the duplex is unwound by an RNA helicase 
to generate a mature, biologically active, single-stranded microRNA and a 
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biologically inactive, unstable minor (or star) strand microRNA (101). For members 
of the let-7 family, this helicase has been identified as p68, however is likely that 
other helicases may facilitate the unwinding of different microRNA duplexes (102). 
Ago-2 then directly binds and retains the mature strand while the Dicer complex 
dissociates liberating the core RISC assembly, the mature microRNA-bound Ago-2 
(103,104). Depending on the cellular, developmental, and physiological context this 
core RISC can associate with other auxiliary proteins to modulate the biological 
activity of the mature microRNA (104). Once loaded with a mature microRNA, the 
RISC assembly guides the mature microRNA to its target mRNA where it proceeds 
to post-transcriptionally regulate gene expression via a variety of mechanisms 
(Figure 1.1).  
MicroRNA Mechanisms Of Action 
 Mature microRNAs are ferried by the RISC assembly to their mRNA targets 
where they act to post-transcriptionally regulate gene expression. MicroRNAs 
associate with their targets by base-pair complementation. In plants, microRNAs are 
generally perfectly complementary to their target mRNAs and bind within the coding 
region or 3’UTR, triggering the RNAi pathway and resulting in mRNA cleavage and 
destruction. In animals, the 5’ “seed sequences” of imperfectly complementary 
microRNAs bind within the 3’UTR of target mRNAs. This interaction results in 
translational inhibition of target mRNAs, however animal microRNAs can also 
facilitate the degradation of mRNA targets, and rarely, stimulate the translation of 
target mRNAs (105-107).  
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 Translation is divided into three discrete stages: initiation, elongation, and 
termination. To date, significant evidence suggests that microRNAs can repress 
translation at both the initiation and post-initiation stages. In support of the inhibition 
of translational initiation hypothesis, sedimentation studies found that microRNA-
bound mRNAs migrate to the top of the gradient, indicating reduced ribosomal 
loading (16,108,109). Furthermore, mRNAs with a non-functional 7-methyl-
guanosine cap or an Internal Ribosome Entry Site (IRES) were not repressed by 
microRNAs, suggesting microRNAs block an early initiation step, possibly involving 
7-methyl-guanosine cap recognition (16,108). Recent studies in C. elegans further 
support microRNA-mediated inhibition of translational initiation. In these studies, let-
7 and lin-4-mediated repression of lin-14 and lin-28 target mRNAs led to the 
decreased association of these mRNAs with polysomes (110). Additional studies in 
human hepatocarcinoma cells also reported the decreased association of CAT1 
mRNA with polysomes in the presence of miR-122 (109). Studies in cell free extracts 
also confirm that the presence of a 7-methyl-guanosine cap is required for 
microRNA-mediated translational repression and that mRNAs containing IRES 
sequences were not repressed by microRNAs (111-114). This analysis also found 
that microRNAs inhibit the association of target mRNAs with the small ribosomal 
subunit and decrease the levels of the 80 s initiation complex (112,113). This 
inhibition was relieved by the addition of purified ElF4E, which enhances ribosomal 
binding to the 7-methyl-guanosine cap (113). Recent studies report that the RISC 
member Ago-2 directly binds to the 7-methyl-guanosine cap, thereby preventing 
ribosome-7-methyl-guanosine cap interaction (115). Other studies report that the 
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RISC assembly associates with ElF6, a protein that prevents ribosome binding to 
mRNA and that depletion of ElF6 alleviated let-7-mediated repression in human cells 
(116). These results strongly support the inhibition of translational-initiation as the 
primary mechanism of microRNA-mediated translational repression.  
 However, there is also substantial evidence suggesting that microRNA 
repression also occurs after the initiation of translation. For example, multiple studies 
have reported the persistent association of repressed mRNAs with polysomes. In C. 
elegans, the lin-14 and lin-28 mRNAs, targets of the lin-4 microRNA, remain 
associated with polysomes despite a decrease in corresponding protein expression 
(15,117). Another study utilizing microRNA mimics enhanced the termination of 
translation post-initiation via ribosomal drop-off (118). Clearly, microRNAs can 
regulate translation via multiple mechanisms. One possible explanation for these 
divergent mechanisms may lie in the heterogeneous nature of the RISC assembly. 
Perhaps different RISC assembly factors influence where their associated 
microRNAs repress the translational process.  
 Multiple reports have identified cytoplasmic P-bodies (or GW bodies) as the 
sub-cellular location of microRNA-mediated translational repression (119). P-bodies 
are discrete foci devoid of ribosomes and enriched in factors involved in translational 
repression and mRNA decay, including Argonaute proteins and microRNA-bound 
mRNAs (120). Also found in P-bodies are GW182 proteins (121). GW182 proteins 
are rich in glycine-tryptophan repeats and also contain numerous RNA recognition 
repeats responsible for their interaction with Argonaute proteins (122,123). GW182 
proteins are downstream components of the RISC assembly and are believed to act 
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as a critical linker of mRNA targets to the RISC assembly. Depletion of GW132 led 
to the ablation of P-bodies and abolished microRNA-mediated gene silencing, 
indicating that GW182 proteins are essential for P-body stabilization and the 
maintenance of microRNA-mediated repression (123,124). 
 MicroRNA-mediated repression is also frequently associated with the 
degradation of mRNA targets. In animal studies and experiments in cell culture 
models and cell-free extracts, overexpression of microRNAs downregulated a large 
number of mRNAs (114,122,125-134). In many cases, these downregulated mRNAs 
have 3’UTR sequences highly complementary to the 5’ seed sequence of the 
overexpressed microRNA. Due to the imperfect binding of animal microRNAs, this 
degradation is likely not occurring through RNAi-mediated cleavage. Instead, 
microRNA-induced mRNA degradation likely occurs through the deadenylation and 
destabilization of the mRNA. This deadenylation occurs in a GW182-dependent 
manner. GW182 recruits the CAF1:CCR4:NOT1 deadenylation complex to the target 
mRNA resulting in deadenylation followed by de-capping by the DCP1:DCP2 
complex and exonucleolytic degradation by the 5’-3’ exonuclease, Xrn1 
(38,122,126,127). MicroRNA-mediated translational repression and mRNA 
deadenylation are independent events as many microRNA targets are translationally 
repressed with no evidence of deadenylation (135,136). The factors determining 
whether a microRNA will act as a translational repressor or a mRNA deadenylator 
are poorly understood and require further investigative scrutiny.  
 In a deviation from the accepted dogma of microRNA-mediated translational 
repression, microRNAs have also been reported to induce the translation of target 
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mRNAs. For example, under conditions of stress (i.e. serum starvation), growth 
arrested cells underwent a transition from microRNA-mediated repression to 
activation of translation. In these cells, Ago-2 associated with Fragile X Related 
Protein 1 (FXR1) to generate a novel RISC, which when bound to miR-369-3 
induced the translation of target TNFα mRNA. Under these same experimental 
conditions, let-7 and a synthetic microRNA also induced the translational activity of 
corresponding reporter assays (137). Additionally, Orom et al. reported that miR-10a 
induced the translation of mRNAs encoding ribosomal proteins via non-classical 
binding to terminal oligo-pyrimidine (TOP) motifs in the 5’UTR under conditions of 
amino acid starvation (138). These reports suggest that microRNAs can induce 
translation under conditions of cellular stress. However, the precise frequency and 
biological significance of this deviation from current microRNA dogma remains 
unclear.  
MicroRNA Functions 
 MicroRNAs were first discovered in C. elegans in 1993 through the use of a 
forward genetic screen (9,17). This founding microRNA, lin-4, was identified via a 
loss-of-function mutation resulting in larval growth arrest. This developmental 
retardation was caused by the failure of lin-4 to repress its target mRNA, lin-14. 
Initially, microRNAs were deemed a phenomenon unique to C.elegans and the 
discovery of microRNAs in higher organisms stalled until 2000 when a second 
microRNA, let-7 was identified by another forward genetic screen in C.elegans 
(139). Depletion of let-7 expression resulted in the failed larval to adult transition. 
Let-7 regulates a number of genes during this transition, including lin-41 (11). This 
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study found that let-7 and the lin-41 target site are highly conserved, providing the 
first evidence that this microRNA:target mRNA interaction may control 
developmental timing in higher organisms (11). Following this discovery, microRNA 
research has expanded exponentially. In fact, traditional cloning and computational 
methods have identified highly conserved microRNAs in plants, flies, rodents, 
humans and numerous other species (3-7,10). To date, there are approximately 940 
annotated human microRNAs in the miRBase registry (22,23). Each of these 
microRNAs can target a predicted 100-200 mRNAs, or approximately 30% of human 
mRNAs, making microRNAs a large class of gene regulatory elements (24). 
Currently, there are 1094 experimentally supported human microRNA mRNA targets 
in the TarBase registry: therefore, approximately 1% of the predicted microRNA: 
target mRNA regulatory relationships have been experimentally validated, 
suggesting that the scientific community has only a minimal understanding of the 
diverse functions of microRNAs (140). 
 It has been proposed that microRNAs can function in two general modalities: 
as developmental “switches” or as “fine-tuners” of gene expression (141). MicroRNA 
“switches” are those microRNAs that reduce target gene expression to undetectable 
or biologically insignificant levels. The founding microRNAs, lin-4 and let-7, are 
examples of switch microRNAs because their expression “turns-off” target gene 
expression during C.elegans development (9,17,139). In humans, the muscle-
specific microRNAs miR-1 and miR-133 act as developmental switches, dramatically 
reducing the expression of their respective targets, histone deacetylase 4 (HDAC4) 
and the splicing protein neuronal polypyrimidine tract-binding protein (nPTB) to 
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positively regulate the differentiation of muscle cells (40). Loss-of-function mutation 
of microRNA “switches” would, expectedly, result in striking developmental 
phenotypes. In support of this hypothesis, the founding microRNAs lin-4 and let-7 
were discovered when their depletion led to growth arrest in C. elegans (9,17,139) 
and the depletion of the microRNA “switch” miR-1 in the mouse resulted in gross 
defects in cardiac development and function (142). MicroRNA “fine-tuners” do not 
significantly reduce the expression of single target mRNA, but instead act as a 
rheostat to set defined expression levels of numerous low-abundance target 
mRNAs. Therefore, depletion of a “fine-tuner” microRNA would not lead to an overt 
phenotype, making this class of microRNAs challenging to study. An example of a 
microRNA “fine-tuner” is the liver-specific miR-122 (130,143). In-vivo anti-sense 
depletion of this microRNA increased the expression of more than 100 low-
abundance mRNAs bearing miR-122 seed sequences in their 3’UTRs (130,143). As 
expected, this mouse did not display an overt disease phenotype, however depletion 
of this microRNA did significantly lower the levels of circulating triglycerides and 
cholesterol, confirming that miR-122 acts as a “fine-tuner” of lipid metabolism 
(130,143).  
 The importance of microRNAs in the regulation of basic biological functions is 
best demonstrated in the Dicer-deficient mouse. These microRNA depleted mice 
exhibited growth arrest and embryonic lethality during gastrulation (74). Conditional 
Dicer-deficient mice have further illuminated the important functional role of 
microRNAs in specific tissues. For example, depletion of Dicer in the mouse T-cell 
compartment reduced proliferation and increased apoptosis of immature T-cells 
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(144) while conditional depletion in the B-cell compartment significantly lowered 
antibody diversity and cell survival (145). Targeted Dicer deletion in the heart 
resulted in heart failure and cardiomyopathy (146) and Dicer-deficient mouse 
embryonic stem cells were unable to proliferate and failed to undergo differentiation 
(147). Clearly, the global ablation of microRNA expression has catastrophic, 
organism-wide consequences, indicting that microRNAs are key regulators of 
fundamental biological processes, including differentiation, proliferation, embryonic 
development, and apoptosis.  
 Further supporting role of microRNAs as key gene expression regulatory 
elements is the observation that microRNA expression or function is frequently 
dysregulated in human diseases. To date, approximately 132 diseases, including 
heart disease, neurological disorders and cancer, have been associated with the 
aberrant expression or function of microRNAs (346 individual microRNAs) (21). The 
first associations between microRNAs and disease found that microRNA expression 
levels are frequently altered in human tumors and that these alterations are often 
global, indicating that microRNA bioprocessing is dysregulated during tumorigenesis 
(148-150). Further studies have identified that the loss of specific “tumor-suppressor 
microRNAs” (miR-15a and miR-16-1) or the increased expression of “oncogenic 
microRNAs” (miR-17-92 polycistron) contributes to the development of 
hematomalignancy (93,151,152). Interestingly, tumors often exhibit microRNA 
expression profiles that differ significantly from adjacent normal tissue (149,153). 
Currently, these distinct microRNA expression profiles are being utilized clinically as 
promising diagnostic and prognostic tools. Newly identified, stably circulating serum 
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microRNAs are also being successfully utilized as a novel biomarkers for the 
detection and diagnosis of cancers and other pathologies, suggesting that these 
serum microRNAs are promising, minimally invasive biomarkers of disease (154).  
Tourette’s Syndrome exemplifies a disease in which aberrant microRNA 
function contributes to the disease phenotype. SLITRK1, a positive regulator of 
neurogenesis, is downregulated in a subset of patients with Tourette’s Syndrome 
(155). In these patients, the miR-189 binding site in the SLITRKI1 3’UTR is mutated, 
increasing the frequency and stability of miR-189 binding, resulting in decreased 
SLITRK1 expression and contributing to the development of Tourette’s Syndrome 
(155). Cancer and Tourette’s Syndrome represent diseases in which microRNA 
dysregulation clearly contributes to pathogenesis: however, in the majority of 
disease:microRNA correlations, how microRNAs functionally contribute to 
pathogenesis is poorly understood. 
MicroRNAs And Apoptosis 
 The Drosophila microRNAs miR-14 and Bantam were first identified as 
apoptotic effectors in 2003 (13,156). Following this discovery, numerous studies 
have identified additional apoptosis effector microRNAs in various organisms. Many 
of these studies specifically cite a causal role for these microRNAs in the 
development of cancer. Importantly, several microRNAs have been implicated in the 
regulation of apoptosis in lymphocytes. The first study implicating a regulatory role 
for microRNAs in lymphocyte tumorigenesis found that a deletion of chromosome 
region 13q14 strongly correlated with the development of chronic lymphocytic 
leukemia (CLL). This region houses microRNAs 15a and 16-1 and the expression of 
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these microRNAs was repressed in 68% of CLL cases studied. The expression of 
the anti-apoptotic oncogene Bcl-2 was inversely correlated with the expression of 
these microRNAs. Furthermore, overexpression of microRNAs 15a and 16-1 in a 
leukemic cell line resulted in reduced expression of Bcl-2 and the induction of 
apoptosis. This evidence suggests that microRNAs 15a and 16-1 are pro-apoptotic 
tumor suppressors (35,151). MicroRNAs can also function as “oncomiRs” in 
lymphocytes. For example, microRNA 155 is significantly upregulated in B cell 
lymphomas. Transgenic overexpression of the microRNA 155 host transcript BIC in 
mice promoted massive lymphomagenesis and decreased survival through an 
unknown mechanism (157-159). Furthermore, other studies have found that the 
chromosome 13q31 locus is amplified in numerous B-cell lymphoma subtypes. This 
locus is home to the microRNA 17-92 polycistron. Adoptive transfer of hematopoietic 
stem cells bearing the 17-19b-1 portion of the polycistron in mice overexpressing the 
cMyc transgene resulted in the rapid onset of malignant lymphomas. These 
lymphomas exhibited resistance to apoptosis and increased levels of proliferation 
(160). Transgenic overexpression of the entire 17-92 polycistron in the 
hematopoietic compartment in the mouse led to the development of 
lymphoproliferative disease and increased lethality. Lymphocytes from these 
animals displayed a reduced sensitivity to Fas-ligand-induced cell death as well as 
increased proliferation. Furthermore, the expression of the two pro-apoptotic 
proteins, Bim and the PTEN tumor suppressor, was decreased in response to 
microRNA 17-92 overexpression (161). Taken together, these studies indicate that 
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microRNAs play a functional role in the regulation of lymphocyte apoptosis and the 
development of hematomalignancy.  
Endogenous and synthetic glucocorticoid steroids are potent inducers of 
lymphocyte apoptosis. Glucocorticoid-induced apoptosis in a key event in immune 
development and the escape of lymphocytes from glucocorticoid-induced apoptotic 
constraint promotes the development of hematomalignancy. Previously, a single 
study profiled the expression of microRNAs during glucocorticoid-induced apoptosis 
of transformed lymphocytes however this study did not describe the mechanism or 
functional consequence of this altered microRNA expression (162). This dissertation 
seeks to examine glucocorticoid-regulation of microRNAs during apoptosis of 
primary thymocytes and determine whether this regulation modulates lymphocyte 
apoptosis. 
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1.2 GLUCOCORTICOIDS 
Glucocorticoids are a class of essential stress-induced steroid hormones 
regulating a variety of cardiovascular, metabolic, homeostatic and immunologic 
functions. Endogenous glucocorticoids are synthesized and secreted under the 
control of the hypothalamic-pituitary-adrenal axis in response to stressors, including 
environmental stress, nociception, and emotion. Stimulation of hypothalamic 
corticotropin-releasing hormone (CRH) secretion prompts the release of adreno-
corticotropic hormone (ACTH) from the pituitary, which induces glucocorticoid 
synthesis within the zona fasciculata of the adrenal cortex. Glucocorticoids auto-
regulate their secretion though negative feedback inhibition of CRH and ACTH 
synthesis and release. In humans, cortisol is the predominant circulating 
glucocorticoid. Once in circulation, natural glucocorticoids are predominately bound 
to corticosteroid-binding globulin (CBG). Due to their lipophilic nature, endogenous 
glucocorticoids are widely bioavailable and easily cross the cell membrane via 
passive diffusion (163,164).  
Glucocorticoids exert their physiological effects through the ubiquitously 
expressed glucocorticoid receptor (GR), a member of the nuclear hormone receptor 
super family of ligand-activated transcription factors. Upon ligand binding, the GR 
translocates to the nucleus where it activates or represses the transcription of 
glucocorticoid-responsive genes. Due to the broad distribution of both 
glucocorticoids and their cognate receptor, glucocorticoid signaling exerts a wide 
range of physiological actions. For example, in the liver and adipose tissue, 
glucocorticoids positively regulate metabolism through the stimulation of 
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gluconeogenesis and lipolysis, respectively. Conversely, in the immune 
compartment, glucocorticoids are largely inhibitory, causing immune suppression 
through the induction of apoptosis and cell cycle arrest and the inhibition of 
inflammation via the repression of pro-inflammatory cytokines (Figure 1.2) (163,164).  
Given their broad bioavailability and diverse physiological effects, synthetic 
glucocorticoids are among the most commonly prescribed drugs for the treatment of 
inflammatory disorders, autoimmune diseases, and sepsis. They are also a mainstay 
in the treatment of hematological malignancies. Numerous high affinity synthetic 
glucocorticoids are clinically available, including prednisone and dexamethasone. 
However, prolonged use of these compounds is complicated by numerous 
deleterious side-effects, such as osteoporosis, hypertension, psychosis, Cushing’s 
syndrome and leucopenia (164). Glucocorticoid use in chemotherapy is limited by 
the development of glucocorticoid resistance. Glucocorticoid resistance in leukemia 
and lymphoma is correlated with a poor prognosis (165-168). The mechanisms 
governing glucocorticoid resistance in these malignancies are an area of 
considerable interest to both the scientific and medical communities. This section will 
review glucocorticoid signaling and glucocorticoid-induced apoptosis of healthy and 
malignant lymphocytes.  
Glucocorticoid Receptor 
The glucocorticoid receptor is a member of the Type I Nuclear Hormone 
Receptor super family. Members of this super family are characterized by the 
formation of homodimers and the presence of three distinct functional domains: the 
C-terminal ligand binding domain (LBD), the internal zinc-finger DNA binding domain 
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(DBD), and the N-terminal transactivation domain (NTD) (169-173). In humans, the 
GR gene (NR3C1) is located on chromosome 5q31.3 and encodes nine exons 
(174). Exon 1 represents the 5’-untranslated region while exons 2-9 are protein 
coding (175). Exon 2 encodes the majority of the amino acids in the N-terminal 
domain. This region houses the AF-1 transactivation domain (amino acids 77-262), 
which interacts with the basal transcription machinery to induce transcription (176). 
The central DNA binding domain is encoded by exons 3-4 and mediates receptor 
binding to glucocorticoid-response elements (GREs) within the promoters of 
responsive genes. The DBD also consists of two conserved zinc fingers, which 
facilitate interaction with the NFκB and AP-1 transcription factors (first zinc finger) as 
well as receptor dimerization (second zinc finger) (177-179). The region between the 
two zinc fingers houses a nuclear export signal (NES) (179-181). A hinge region 
adjacent to the DNA binding domain contains a nuclear localization signal at amino 
acids 491-498 (182). Finally, exons 5-9 encode the C-terminal ligand-binding 
domain. This region is responsible for ligand binding, cofactor binding, and also 
contains a weak AF-2 transactivation domain (183-186). Following translation, the 
mature glucocorticoid receptor resides in the cytosol complexed with an hsp90 
dimer, p23 stabilizing protein and a variety of co-chaperones (187,188).  
The predominant GR expressed in human tissues is the full-length GRα 
isoform (189). However, there are numerous additional GR protein isoforms 
generated from the single GR gene via alternative splicing and the use of alternative 
translation initiation sites. Alternative splicing of GR pre-mRNA generates 5 distinct 
GR protein isoforms, namely GRα, GRβ, GRγ, GR-A and GR-P. Of these, GRα and 
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GRβ are the most widely expressed. These two receptor isoforms differ in their 
carboxyl termini due to the use of alternative splicing sites within exon 9 (190). GRα 
is produced from the splicing of exon 8 to the proximal end of exon 9, thus 
generating a 777 amino acid protein. Exon 9 contributes an additional 50 residues to 
the LBD of the GRα receptor. GRβ is created from the splicing of exon 8 to the distal 
end of exon 9 generating a shorter protein of 742 residues, including 15 unique C-
terminal residues contributed by exon 9. This splice site is predominantly found in 
humans and has not been identified in the mouse, explaining the lack of GRβ 
expression in mice (191). The 15 C-terminal residues contributed by exon 9 render 
GRβ unable to bind glucocorticoids or transactivate glucocorticoid-responsive 
reporter genes (192,193). Initially, GRβ was described solely as a dominant negative 
inhibitor of GRα transactivation (193-195). This inhibition occurs through both direct 
interaction with GRα as well as through competitive recruitment of transcriptional 
coactivators (196). Deletion of the 15 unique C-terminal amino acids rendered GRβ 
unable to repress GRα transactivation (195). In contrast to earlier findings, recent 
studies have described a direct transcriptional role for GRβ. For example, hGRβ, 
expressed in the absence of hGRα, possesses intrinsic transcriptional activity. For 
example, GRβ can selectively bind the glucocorticoid receptor antagonist RU-486 
and this binding diminishes its intrinsic transcriptional activity (197). More recently, 
Kelly et al. found that GRβ is capable of repressing transcription from the cytokine 
interleukin 5 (IL-5) and IL-13 promoters via recruitment of histone deacetylase I 
(198). 
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The GRγ splice variant harbors an additional three base insertion in the DNA 
binding domain resulting in the insertion of an arginine residue between the two zinc 
fingers, thus reducing its transcriptional capacity. The GRγ isoform is largely 
expressed in lymphocytes (3.8-8.7% of total GR mRNA) (199). However, the 
evaluation of GRγ protein expression in lymphocytes is hampered by the absence of 
a specific GRγ antibody. The GR-A splice variant lacks exons 5-7, resulting in a 
truncated ligand-binding domain and impaired transactivation activity. Finally, the 
GR-P splice variant lacks exons 8 and 9, also resulting in a truncated ligand-binding 
domain lacking the ability to bind glucocorticoids (200).  
Additional GR isoforms are generated through the use of alternative 
translation initiation sites. These isoforms were first identified by immunoblotting as a 
GRα doublet migrating at 94kD and 91kD (201,202). The existence of additional 
GRα isoforms was confirmed by the identification of an in-frame internal translation 
initiation site at methionine 27. Use of this site is responsible for the generation of 
the 91-kD species of GRα, now termed GRα-B (201). Further scanning for internal 
translational start sites revealed the presence of six additional GRα translational 
isoforms, GRα-C1, C2, C3, D1, D2, and D3 (202). These isoforms differ only in the 
length of their N-termini and all bind glucocorticoids with similar affinity. However, 
these isoforms possess unique gene expression profiles and transcriptional 
activities. For example, GRα-C3 is the most transcriptionally active, even enhancing 
the basal transcriptional activity of GRα-A (202). Conversely, the GRα-D isoform is 
the least transcriptionally active and unable to induce apoptosis in a stably 
overexpressing osteosarcoma cell line (203). Given the distinct actions of these 
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diverse GR protein isoforms, alterations in their intracellular ratios may influence the 
lymphoid response to glucocorticoids.  
Glucocorticoid receptor expression is under the control of three distinct 
promoters, 1A, 1B and 1C. Alternative promoter usage results in transcripts bearing 
exons 1A, 1B and 1C. Alternative splicing of these exons leads to the generation of 
nine alternative exon 1 splice variants (1A, 1B, 1C, 1D, 1E, 1F, 1H, 1I and 1J) (204-
206). Further splicing of exons 1A and 1C yield exons 1A1, 1A2, 1A3 and exons 
1C1, 1C2, and 1C3 (204,205). These assorted transcripts all encode the same 
protein, however, selective promoter usage may influence downstream splicing and 
translation initiation events as well as GR protein levels and ultimately, 
responsiveness to glucocorticoid treatment (204,206-208).  
 
Glucocorticoid Receptor Signaling 
Ligand-free GR exists in the cytoplasm as a multiprotein heterocomplex 
associated with an Hsp90 dimer, p23 stabilizing protein, and various immunophilin 
chaperone proteins (188,209). Upon ligand binding, the GR heterocomplex 
undergoes a conformational change, releasing the GR from cytoplasmic 
sequestration, promoting receptor homodimerization and nuclear translocation of the 
GR homodimer (182,210-214). In the nucleus, the activated GR homodimer binds 
specific DNA elements, or glucocorticoid-response elements (GRE) within the 
promoter regions of glucocorticoid responsive genes (Figure 1.3). The consensus 
GRE is composed of two hexamer half sites separated by three random nucleotides. 
A majority of GREs contain the hexamer half-site sequence TGTTCT. The number 
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and location of these GREs influences the intensity of the transcriptional response 
(215). Once bound to the GRE, the GR homodimer recruits transcriptional 
coactivators as well as the basal transcriptional machinery to the transcription start 
site. These coactivators include (but are not limited to) CREB binding protein (CBP), 
steroid receptor coactivator-1 (SRC-1), GR interacting protein-1 (GRIP-1), p300, and 
SWI/SNF (216,217). These coactivators induce histone acetylation, thus allowing for 
transactivation of glucocorticoid-response genes.  
The activated GR homodimer is also capable of gene repression. GR can 
directly interact with DNA via negative GREs within the promoter regions of target 
genes (218,219). This interaction inhibits the transcription of genes associated with 
these promoters. Promoters with described nGREs include the CRF, osteocalcin 
and prolactin promoters (220-222). Alternatively, GR can regulate transcription 
independent of GR binding through direct interaction with other nuclear transcription 
factors, such as NFκB, AP-1, STAT5 and STAT3, thus modulating the transcription 
of genes under the control of these transcription factors (Figure 1.3) (223-228). 
GR-signaling has been reported to induce rapid effects in the cytoplasm 
within minutes of ligand binding. For example, upon ligand binding, Src kinase is 
released from the cytosolic GR heterocomplex, resulting in lipocortin-1 activation 
and inhibition of arachidonic acid release. The activation of Src required ligand-
bound GR, but was independent of transactivation (229). Furthermore, 
glucocorticoids have long been known to alter cytoplasmic ion content, causing rapid 
alterations in calcium, sodium and potassium concentrations (230-232). 
Glucocorticoids also cause rapid increases in the mitochondrial production of 
28
reactive oxygen species, ceramide, hydrogen peroxide, and the lysosomal release of 
Cathepsin B (233-236). Interestingly, glucocorticoids have been reported to induce 
the translocation of GR to the mitochondria in both thymocytes and lymphoma cells 
(237). This mitochondrial GR may mediate mitochondrial production of reactive 
oxygen species and ceramide as well as rapid calcium mobilization following 
glucocorticoid treatment (238). 
Recently, membrane bound GR (mGR) has been suggested in T 
lymphocytes. Glucocorticoid treatment inhibits T-cell receptor (TCR) signaling via the 
mGR. This inhibition occurs through the disruption of the lymphocyte specific protein 
tyrosine kinases Lck and Fyn. These kinases, anchored to Hsp90, are components 
of the TCR-linked mGR-multiprotein complex. Glucocorticoid treatment results in the 
rapid dissociation of Lck and Fyn from the multiprotein complex, leading to reduced 
phosphorylation of Lck/Fyn substrates and impaired initiation of TCR signaling. This 
diminished TCR signaling suppresses downstream cytokine synthesis, cellular 
migration and proliferation of T-lymphocytes (239,240).  
Glucocorticoid-Induced Apoptosis  
The progression of glucocorticoid-induced apoptosis is a multifaceted process 
with contributions from both genomic and cytoplasmic signaling events. Genomic 
events alter the protein content of the cell, creating an environment favorable to the 
execution of the apoptotic pathway. There is significant evidence indicating that the 
transactivation activity of the GR is required for the initiation of glucocorticoid-
induced apoptosis. For example, glucocorticoid-induced apoptosis of lymphocytes 
does not progress in the presence of actinomycin D or cycloheximide, indicating a 
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requirement for de novo transcription and translation in the execution of the 
apoptotic cascade (232,236,241-243). The finding that an activation deficient GR 
mutant possessing unaltered transrepression capability fails to initiate glucocorticoid-
induced apoptosis further supports this observation (244). Finally, thymocytes 
isolated from a knock-in mouse harboring a point mutation preventing receptor 
dimerization, and thus GR transactivation, also failed to undergo glucocorticoid-
induced apoptosis (245).  
Numerous laboratories have performed genome-wide microarray analysis to 
identify genes differentially regulated during glucocorticoid-induced apoptosis (246-
252). However, to date, only a few genes have been assigned a functional role in the 
regulation of glucocorticoid-induced apoptosis. Most notably, the expression of the 
pro-apoptotic BH3-only Bcl-2 family member Bim is induced by glucocorticoid-
treatment in murine lymphoma cell lines, human leukemic cell lines, mouse primary 
thymocytes, and human primary CLL and ALL samples (166,249,252-254). The 
mechanism of induction is likely indirect, as there is no GRE in the promoter region 
of the Bim gene (252,255). One potential mechanism of Bim induction is via the 
induction of the Fox03A/FKHRL1 transcription factor, which is upregulated by 
glucocorticoids (256,257). A more recent study found that the activity of the 
serine/threonine kinase GSK3 is a key mediator of glucocorticoid-induced Bim 
upregulation (258). The induction and activation of Bim leads to downstream 
activation of the apoptotic mediators Bax and Bak (259). Once activated, these 
mediators destabilize the mitochondrial membrane potential, a hallmark of the 
intrinsic mitochondrial apoptosis pathway (259). This upregulation of Bim is likely an 
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important mediator of glucocorticoid-induced apoptosis, as thymocytes from 
homozygous Bim knockout mice exhibit decreased sensitivity to glucocorticoid-
induced apoptosis (260). Furthermore, in-vitro studies utilizing shRNA or siRNA 
targeting the various Bim transcripts confirm a substantial role for Bim induction in 
the progression of glucocorticoid-induced apoptosis (261-263). 
The role of glucocorticoid-induced leucine zipper (GILZ) is an area of 
expanding interest in the study of glucocorticoid-induced apoptosis. GILZ was first 
identified as a glucocorticoid-response gene by a systemic screen for genes 
responsive to glucocorticoids in the thymus (264). Due to the presence of three 
GREs in the GILZ promoter, glucocorticoid-induction of GILZ expression is direct 
and robust (265). The strongest evidence that GILZ may mediate glucocorticoid-
induced apoptosis is provided by studies of GILZ transgenic mice. In these mice, the 
GILZ transgene is specifically targeted to the T-cell compartment. Primary 
thymocytes from these mice were resistant to TCR-induced apoptosis. However, 
they exhibited augmented glucocorticoid-induced apoptosis due to reduced 
expression of the Bcl-2 family member, Bcl-XL, as well as increased activation of 
caspase-8 and caspase-3 (266). GILZ also mediates glucocorticoid-induced cell 
cycle arrest through direct interaction with and inhibition of the proliferative Ras and 
Raf oncogenes (267). 
In addition to Bim and GILZ, glucocorticoids rapidly transactivate the stress 
gene Dexamethasone-induced gene 2 (Dig2) in murine lymphoma cell lines. 
Interestingly, Dig2 overexpression reduced the sensitivity of these cells to 
glucocorticoid-induced apoptosis, suggesting a prosurvival function for this gene 
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(268). Granzyme A is upregulated following glucocorticoid treatment in B-ALL cells. 
Pharmacological inhibition of Granzyme A blunted the apoptotic response, indicating 
this enzyme is an effector of glucocorticoid-induced apoptosis (269). T-cell death-
associated gene 8 (TDAG8) is rapidly induced by glucocorticoids in thymocytes. 
Thymocytes from TDAG8 transgenic mice exhibited increased activation of 
caspases-3, -8, and -9 following glucocorticoid exposure (270). However, 
thymocytes from TDAG8 deficient mice remained sensitive to glucocorticoid-induced 
apoptosis, suggesting a minor role for TDAG8 in glucocorticoid-induced apoptosis 
(271). Glucocorticoid exposure represses the pro-survival oncogene c-Myc in human 
leukemic CEM cells (252). Furthermore, glucocorticoids repress the glycolytic 
Hexokinase II enzyme (272). Hexokinase II acts as a stabilizer of the mitochondrial 
voltage dependent anion channel (VDAC). Interestingly, Hexokinase II 
overexpression abrogated glucocorticoid-induced apoptosis via inhibition of 
mitochondrial destabilization (273). In summary, glucocorticoids regulate the 
transcription of numerous genes, the expression of which influences cellular 
progression through the glucocorticoid-induced apoptotic pathway. 
Glucocorticoids also cause rapid and sustained increases in cytosolic calcium 
concentration in thymocytes, lymphoma cells and B-lymphoblasts (232,274-278). 
Buffering of cytosolic calcium or culture in calcium-free media prevented 
glucocorticoid-induced apoptosis of primary thymocytes (232). Interestingly, 
pharmacological inhibition of the calcium binding protein calmodulin inhibited DNA 
fragmentation without interfering with cytosolic calcium increase, suggesting that 
calmodulin mediates the downstream apoptotic effect of glucocorticoid-induced 
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calcium mobilization (279). However, the precise role of calcium mobilization in 
glucocorticoid-induced apoptosis remains controversial. A subsequent study 
reported that chelation of intracellular calcium inhibits DNA fragmentation, but not 
glucocorticoid-induced apoptosis in primary thymocytes (280). Thus, calcium 
mobilization is likely required for endonuclease activation, but not other aspects of 
glucocorticoid-induced apoptosis.  
Glucocorticoids also cause a net potassium efflux in thymocytes and CEM T-
ALL cells (281,282). This potassium loss enhances apoptosis in thymocytes and 
normal intracellular potassium levels inhibit DNA fragmentation and caspase-3 
activation in lymphocytes (230,278). Furthermore, pharmacological inhibition of 
plasma membrane potassium channels in primary thymocytes effectively inhibited 
glucocorticoid-induced apoptosis through the prevention of cytosolic potassium loss 
and inhibition of mitochondrial membrane destabilization (283).  
Glucocorticoids (ranging from 10 7 to 10 12 M) induce a rapid increase in 
intracellular ceramide concentrations in primary thymocytes within fifteen minutes of 
treatment (236). This increase is receptor dependent, as suggested by co-treatment 
with the GR antagonist RU-486 (236). Furthermore, pharmacological inhibition of 
ceramide biosynthesis prevented apoptosis in glucocorticoid-treated thymocytes 
(236). The generation of reactive oxygen species is also dramatically increased in 
response to glucocorticoids (233). This increase accompanies a decrease in the 
mRNA levels of antioxidant enzymes and contributes to glucocorticoid-induced cell 
death (284). Additionally, co-treatment with an exogenous thiol antioxidant inhibits 
glucocorticoid-induced apoptosis (234). Moreover, in the absence of oxygen, cell 
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death is prevented; suggesting that the generation of reactive oxygen species may 
be an important step in the progression of glucocorticoid-induced apoptosis (285). 
Finally, glucocorticoids induce a rapid translocation of GR to the mitochondria in 
glucocorticoid-sensitive cells (237). Overexpression of a GR species specifically 
targeted to the mitochondria was sufficient to induce apoptosis, perhaps through the 
mediation of mitochondrial reactive oxygen species and ceramide production as well 
as the rapid calcium mobilization following glucocorticoid exposure (237). These 
rapid cytoplasmic effects are likely participants in the complex, multi-component 
glucocorticoid-induced apoptosis-signaling pathway.  
 The glucocorticoid-induced apoptosis pathway culminates in the activation of 
the caspase cascade. Caspases are a family of proteases that cleave substrates at 
aspartate residues, mediating the dramatic morphological and biochemical changes 
occurring during apoptosis (286). Studies utilizing broad caspase inhibitors have 
found that glucocorticoid-induced apoptosis requires caspase activation (287-290). 
Caspase activation occurs through two broadly conserved pathways, the extrinsic 
and intrinsic apoptosis pathways. In the extrinsic pathway, ligands such as Fas or 
TNF bind cognate receptors on the cell surface, initiating the caspase cascade via 
activation of caspase 8 (291). The second pathway, the intrinsic or mitochondrial 
mediated pathway, involves disruption of the mitochondrial membrane by the pro-
apoptotic Bcl-2 family members Bim, Bax and Bak, leading to the release of 
Cytochrome-c and Apoptotic peptidase activating factor 1 (Apaf-1) and subsequent 
activation of caspase-9 (292). Both pathways culminate in the activation of 
downstream of effector caspases (caspases-3, -7, and -6); (293).  
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 There is evidence suggesting that glucocorticoid-induced apoptosis proceeds 
via the intrinsic mitochondrial pathway. Thymocytes from Apaf-1 and caspase-9 
deficient mice exhibited reduced sensitivity to glucocorticoid-induced apoptosis (294-
296). Therefore, in a simplified model of glucocorticoid-induced apoptosis, 
glucocorticoid exposure leads to the regulation of genes involved in the initiation of 
apoptosis, namely the pro-apoptotic Bcl-2 family member, Bim. Bim transactivation 
leads to the activation of downstream apoptotic mediators, Bax and Bak. Upon 
activation, Bax and Bak mediate disruption of the mitochondrial membrane potential 
and the subsequent release of Apaf-1 and Cytochrome-c into the cytosol. The 
mitochondria is also responsible for some of the rapid, glucocorticoid-mediated 
cytoplasmic effects including calcium mobilization and the production of reactive 
oxygen species and ceramide, all of which may contribute to the progression of 
glucocorticoid-induced apoptosis. Apaf-1 and Cytochrome-c release leads to the 
activation of caspase 9, the subsequent activation of downstream effector caspases 
and the execution of glucocorticoid-induced apoptosis (Figure 1.4).  
Glucocorticoid-Induced Apoptosis and Immune Development 
In the highly coordinated process of T-lymphocyte development, bone marrow 
progenitors migrate to the thymus where they undergo a transition to double 
negative (CD4-8-) immature thymocytes (297). Following random rearrangement of 
the TCR α and β genes, cells become double positive (CD4+8+) and undergo 
selection based on the specificity of the TCR for self peptides bound to MHC-
encoded molecules (298). Double positive thymocytes with TCRs bearing low avidity 
for self-antigen/MHC undergo “death by neglect”. Thymocytes with TCR bearing 
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high avidity for self-antigen/MHC undergo TCR activation-induced apoptosis 
(negative selection). Only cells bearing TCRs with intermediate avidity for self-
antigen/MHC are rescued from the neglect or negative selection cell death 
programs. These cells undergo positive selection, becoming either CD4+ or CD8+ 
cells. Upon maturation, single positive T-cells enter the periphery (299).  
 How the TCR induces cell death during both neglect and negative selection 
while simultaneously rescuing cells from cell death during positive selection is an 
area of considerable research. A role for systemic glucocorticoids in the regulation of 
thymocyte development was first suggested in 1924, when it was demonstrated that 
bilateral adrenalectomy leads to thymic hypertrophy (300). It has been proposed that 
glucocorticoids interact with TCR-signaling in a relationship termed “mutual 
antagonism”. The first evidence in support of the mutual antagonism model reported 
that stimulation of the TCR protected T-cells from glucocorticoid-induced apoptosis. 
Conversely, glucocorticoids prevented TCR activation-induced cell death in the 
same model system, thus coining the phrase “mutual antagonism”. (301,302). In this 
model, glucocorticoids are key modulators of the “death by neglect” of low avidity 
TCR-bearing thymocytes (303,304). In addition, glucocorticoids interfere with the 
TCR-induced death signaling in cells with intermediate avidity TCRs, allowing these 
cells to escape TCR-induced apoptosis and undergo positive selection (301,302). 
However, the TCR activation-induced apoptotic signaling in double positive 
thymocytes bearing high avidity TCRs overwhelms glucocorticoid antagonism, 
allowing for the deletion of these cells during negative selection (305).  
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TCR signaling activates extracellular signal-related kinase (ERK) signaling 
(306). ERK is responsible for rapid phosphorylation and inactivation of Bim, a key 
modulator of the glucocorticoid-induced apoptotic pathway (307). Accordingly, TCR 
may antagonize glucocorticoid signaling via ERK activation and Bim inactivation. 
Alternatively, glucocorticoid signaling results in the rapid dissociation of the 
lymphocyte specific kinases LCK and FYN from the TCR complex, thus inactivating 
TCR signaling (240). Therefore, one potential mechanism of glucocorticoid 
antagonism of TCR is through disruption of the TCR complex. In summary, in this 
model of mutual antagonism, glucocorticoids act as a rheostat, modulating the 
threshold for TCR activation-induced apoptosis during thymocyte selection.  
 In-vitro evidence for the mutual antagonism model was generated by 
experiments in fetal thymic organ culture (FTOC). Pharmacological inhibition of 
glucocorticoid production or glucocorticoid signaling sensitized cells to TCR-induced 
apoptosis, ultimately altering the T-cell repertoire (308,309). Furthermore, in-vivo 
knockdown of GR in the T-cell compartment dramatically reduced thymus size due 
to a decrease in the number of double positive and single positive thymocytes. Thus, 
the absence of glucocorticoid signaling in-vivo sensitized double positive thymocytes 
to negative selection (310). However, more recent studies of T-cell specific GR 
knockout mice detected no abnormality in thymocyte development (311,312). 
Conversely, additional studies modulating GR expression in the thymus report 
dramatic alterations in thymic cellularity and thymocyte maturation (310,313,314). 
Therefore, the precise role of glucocorticoids in thymocyte development remains 
controversial.  
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The therapeutic potential of synthetic glucocorticoids for the treatment of 
hematological malignancies was first suggested in 1943, when the administration of 
hydroxycorticosterone resulted in apoptosis of malignant lymphocytes in the mouse 
(315,316). Subsequently, synthetic glucocorticoids were implemented in the clinical 
treatment of leukemia and lymphoblastomas (317,318). Today, glucocorticoids are 
central in the treatment of hematological malignancies and are utilized as adjuvants 
in a majority of chemotherapeutic regimens. Chemotherapy of hematological 
malignancies consists of three phases: induction of remission, intensification (or 
consolidation), and maintenance of remission. The induction phase involves the 
rapid destruction of malignant cells in order to achieve remission. Remission is 
defined as the presence of fewer than 5% malignant cells in the bone marrow and 
periphery. The intensification phase utilizes chemotherapy to further reduce tumor 
burden and may consist of bone marrow stem cell transplantation. Finally, 
maintenance of remission utilizes combination therapies to maintain remission and 
prevent relapse (319). Currently, synthetic glucocorticoids are cornerstone 
components of chemotherapeutic regimens in the treatment of Acute Lymphoblastic 
Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), 
Hodgkin’s Disease, and Non-Hodgkin’s Lymphomas. 
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1.3 PERSPECTIVE 
This chapter has surveyed the current literature describing microRNA 
biogenesis and physiological functions, with a specific focus on microRNA-mediated 
regulation of programmed cell death in lymphoid cells. This chapter also introduced 
glucocorticoid-induced apoptosis as a key modulator of immune development and 
function via the induction of apoptosis during thymocyte selection. Furthermore, the 
glucocorticoid receptor is a sensor of environmental stress and endogenous 
glucocorticoids influence the response of the immune system to environmental 
stress and toxic insult. Therefore, understanding the mechanisms governing 
glucocorticoid-induced apoptosis of lymphocytes is an important contribution to 
toxicological research. Additionally, microRNAs are emerging as promising 
biomarkers of malignant disease and toxic injury, as well as potential therapeutic 
targets for the amelioration of malignant disease and tissue injury. These emerging 
novel functions of microRNAs have generated a great deal of interest among the 
pharmacology, toxicology and cancer biology research communities. The broad 
objective of the research presented in this dissertation is to delineate the potential 
regulatory role of microRNAs in glucocorticoid-induced apoptosis of lymphocytes. 
The research described in this dissertation establishes an “apoptotic signature” of 
microRNA expression in apoptotic primary thymocytes and further delineates the 
regulatory role of microRNAs in glucocorticoid-induced apoptosis. The following 
specific questions were addressed in these studies: 
1. Are microRNAs differentially expressed in response to glucocorticoid-
induced apoptosis of primary thymocytes? 
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2. What is the potential mechanism of altered microRNA expression 
during glucocorticoid-induced apoptosis? 
3. What is the effect of altered microRNA expression on the progression 
of glucocorticoid-induced apoptosis? 
 
The studies presented in Chapter 2 and Appendix 1 address these specific 
questions and describe the prevalent downregulation of microRNAs and their 
processing enzymes during glucocorticoid-induced apoptosis and further delineates 
the functional contribution of altered microRNA expression to the progression of 
glucocorticoid-induced apoptosis. Chapter 3 describes a novel approach to 
microRNAnome profiling of primary thymocyte subpopulations specifically displaying 
the morphological characteristics of glucocorticoid-induced and spontaneous 
apoptosis. Finally, Chapter 4 presents a detailed summary of the insights gained in 
these studies and proposes promising directions for future research.  
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1.5 FIGURES 
Figure 1.1 MicroRNA biogenesis and mechanism of action. MicroRNAs are non-
coding, single stranded, ~21mer RNAs that post-transcriptionally regulate gene 
expression. MicroRNAs are transcribed from host genes by RNA Polymerase II to 
yield a primary miRNA (pri-miRNA) transcript. This pri-miRNA transcript is 
processed in the nucleus by the RNase III enzyme, Drosha and the double-stranded 
RNA-binding protein, DGCR8/Pasha to form a pre-miRNA hairpin. Following 
processing, the ~70 nucleotide hairpin is exported from the nucleus. In the 
cytoplasm, the RNAse III enzyme Dicer cleaves the hairpin to yield a 22 nucleotide 
miRNA: miRNA* duplex. This duplex is then unwound to generate a mature, single-
stranded miRNA. The mature miRNA is incorporated into the microRNA-induced 
silencing complex (miRISC). The multi-protein miRISC complex retains the mature 
strand of the microRNA and guides the complex to the target mRNA in order to 
regulate gene expression. 
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Figure 1.2 Pleiotrophic effects of glucocorticoids in responsive tissues. 
Endogenous glucocorticoids are generated in response to various stressors, 
including emotion and nociception. The subsequent physiological actions of 
glucocorticoids in  responsive tissues are denoted as stimulatory (dashed line) or 
inhibitory (dotted line). 
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Figure 1.3 Mechanisms of glucocorticoid-regulated gene expression. Ligand 
binding liberates the GR from cytosolic sequestration, leading to rapid nuclear 
translocation and homodimerization. In the nucleus, GR can activate gene 
transcription through direct binding to GREs in the DNA or through stimulatory 
interactions with transcription factors such as STAT5. GR can also repress gene 
expression by directly interacting with nGREs in the DNA, or through inhibitory 
protein–protein interactions with transcription factors including NFκB. 
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Figure 1.4 Glucocorticoid-induced apoptosis signaling cascade. In this 
abbreviated model, glucocorticoids regulate the expression of apoptosis-effector 
genes, namely the pro-apoptotic Bcl-2 family member, Bim. Bim transactivation 
leads to the activation of downstream apoptotic mediators, Bax and Bak. Upon 
activation, Bax and Bak mediate disruption of the mitochondrial membrane potential 
and the subsequent release of Cytochrome-c and Apaf-1 into the cytosol. Apaf-1 
and Cytochrome-c release leads to the activation of caspase 9, the subsequent 
activation of downstream effector caspases and the execution of glucocorticoid-
induced apoptosis. The mitochondria is also responsible for some of the rapid, 
glucocorticoid-mediated cytoplasmic effects including calcium mobilization and the 
production of reactive oxygen species and ceramide, all of which may contribute to 
the progression of glucocorticoid-induced apoptosis. 
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CHAPTER 2 
 
 
 
GLUCOCORTICOIDS INDUCE DYSREGULATION OF 
MICRORNA EXPRESSION AND PROCESSING DURING 
LYMPHOCYTE APOPTOSIS 
 
 
 
 
 
 
 
2.1 ABSTRACT 
Glucocorticoids modulate immune development and function through the induction 
of lymphocyte apoptosis via mechanisms requiring alterations in gene expression. 
Recently, short, non-coding microRNAs have been identified as key regulators of 
lymphocyte function: however, it is unknown whether glucocorticoids regulate non-
coding microRNAs and whether this regulation may contribute to lymphocyte 
apoptosis. We now show by both microarray and deep sequencing analysis that 
mature microRNAs are substantially repressed during glucocorticoid-induced 
apoptosis of primary rat thymocytes. Mechanistic studies revealed that primary 
microRNA transcripts were not repressed, whereas the expression of the key 
microRNA processing enzymes, Dicer, Drosha and DGCR8/Pasha, were 
significantly reduced at both the mRNA and protein levels during glucocorticoid-
induced apoptosis. To delineate the role of Dicer depletion and microRNA 
repression in apoptosis, we silenced Dicer expression in two human leukemic cell 
lines and demonstrated that Dicer depletion significantly enhanced glucocorticoid-
induced apoptosis in both model systems. Finally, in-vitro and in-vivo overexpression 
of the microRNA 17-92 polycistron, which was repressed significantly by 
glucocorticoid treatment in both our microarray and deep sequencing studies, 
blunted glucocorticoid-induced apoptosis. These studies provide evidence of altered 
post-transcriptional microRNA expression and the dysregulation of the microRNA 
bioprocessing pathway during glucocorticoid-induced apoptosis of lymphocytes, 
suggesting a role for microRNA processors and specific microRNAs in cell life/death 
decisions. 
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2.2 INTRODUCTION 
Recently, non-coding microRNAs have emerged as important gene 
expression regulatory elements. Transcribed by RNA Polymerase II, primary 
microRNAs undergo extensive post-transcriptional processing by the nuclear RNase 
III enzyme Drosha and its co-factor DiGeorge Syndrome Critical Region Gene 8 
(DGCR8/Pasha) followed by Ran-GTP/Exportin-5 dependent nuclear export. In the 
cytoplasm, microRNA precursors are further cleaved by the RNase III enzyme Dicer 
to yield a microRNA duplex. The biologically active, mature, single-stranded 
microRNA is then incorporated into the microRNA-induced silencing complex 
(miRISC). The microRNA-bearing miRISC proceeds to affect gene expression 
through the inhibitory engagement of complimentary “seed sequences” within the 
3’UTRs of target mRNAs, resulting in translational inhibition (1,2).  
Through the modulation of gene expression, microRNAs are key effectors of 
fundamental biological processes including development, differentiation and 
apoptosis (3). Apoptosis of lymphocytes is a highly coordinated process governing 
the development of the T-cell repertoire during thymocyte selection as well as the 
emergence of lymphoproliferative disease due to the escape of malignant cells from 
apoptotic constraint. Recently, microRNAs have been implicated in both the 
regulation of lymphocyte apoptosis and the development of hematomalignancy. For 
example, microRNAs 15 and 16 are strongly downregulated in chronic lymphocytic 
leukemia and the expression of the anti-apoptotic oncogene Bcl-2 is inversely 
correlated with the expression of these microRNAs (4,5). Furthermore, 
overexpression of microRNAs 15 and 16 in a leukemic cell line resulted in the 
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reduced expression of Bcl-2 and the induction of apoptosis, suggesting a pro-
apoptotic tumor suppressor function for microRNAs 15 and 16 in lymphocytes (6). 
Conversely, members of the microRNA 17-92 polycistron are upregulated in B-cell 
lymphomas. Adoptive transfer of hematopoietic stem cells bearing a truncated 
portion of the 17-92 polycistron in cMyc transgenic mice resulted in the rapid onset 
of malignant lymphomas. These lymphomas exhibited resistance to apoptosis and 
increased proliferation (7). Transgenic overexpression of the entire 17-92 polycistron 
in the murine hematopoietic compartment led to the development of 
lymphoproliferative disease and increased lethality. Lymphocytes derived from these 
animals displayed reduced sensitivity to Fas-ligand-induced cell death as well as 
increased proliferation (8). Finally, the expression of the pro-apoptotic proteins, Bim 
and PTEN, was decreased in response to microRNA 17-92 overexpression, 
suggesting an anti-apoptotic oncogenic function for the miR-17-92 polycistron in 
lymphocytes. 
 Glucocorticoids are key effectors of lymphocyte development through the 
induction of apoptosis and the mutual antagonism of TCR activation-induced 
apoptosis during thymocyte selection (9). Owing to their ability to induce rapid 
apoptosis of lymphocytes, synthetic glucocorticoids are also critical components of 
hematomalignant chemotherapy regimens. Glucocorticoid-induced apoptosis of 
lymphocytes is a multifaceted process, requiring signaling through the glucocorticoid 
receptor (GR) and the subsequent transactivation of apoptotic effector genes (10-
13). The requirement for de novo transcriptional events in the execution of 
glucocorticoid-induced apoptosis is well established. However, it is not clear whether 
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the expression of microRNAs is altered during glucocorticoid-induced apoptosis of 
lymphocytes, and if so, whether such alterations contribute to the cell death process. 
Here, we provide evidence of prevalent post-transcriptional repression of microRNA 
expression during glucocorticoid-induced apoptosis of primary rat thymocytes and 
further demonstrate the repression of the microRNA bioprocessors, Dicer, Drosha 
and DGCR8/Pasha. Additionally, the stable depletion of Dicer in glucocorticoid-
sensitive leukemic cell lines significantly enhanced glucocorticoid-induced apoptosis 
and overexpression of the glucocorticoid-repressed microRNA 17-92 polycistron 
blunted glucocorticoid-induced apoptosis, indicating that the dysregulation of 
microRNA expression and processing contributes to the progression of 
glucocorticoid-induced lymphocyte apoptosis. 
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2.3 RESULTS 
Repression of microRNA expression during glucocorticoid-induced apoptosis 
For these studies, primary rat thymocytes, a classic model of glucocorticoid-
induced apoptosis, were cultured in-vitro in the presence or absence of the synthetic 
glucocorticoid dexamethasone for 6 hours. Apoptotic progression was monitored in 
control and glucocorticoid treated cells via flow cytometric analysis of 
phosphatidylserine exposure, plasma membrane integrity and caspase-3 activation. 
Following 6 hours of glucocorticoid treatment we observed an apoptotic population 
of cells. These cells exhibited phosphatidylserine externalization as determined by a 
significant increase in Annexin-FITC fluorescence and decreased plasma membrane 
integrity demonstrated by a modest increase in propidium iodide fluorescence 
(Figure 2.1A). These cells also exhibited an increase in caspase-3 activity 
determined by an increase in CaspaTag fluorescence, indicating the clear induction 
of apoptosis following 6 hours of glucocorticoid treatment (Figure 2.1B). These 
apoptotic indicators were more pronounced following 12 hours of treatment resulting 
in significant cell death as determined by propidium iodide uptake (Figure 2.1A and 
B). Therefore we performed our microRNA expression analysis early in the apoptotic 
process (prior to cell death) following 6 hours of glucocorticoid treatment.  
After 6 hours of treatment, total RNAs from control and glucocorticoid treated 
cells were prepared and subjected to microRNA microarray analysis. Of the 350 
microRNAs represented on our chip, 56 were differentially expressed in response to 
glucocorticoid-induced apoptosis (Figure 2.2A). Surprisingly, the majority of these 
microRNAs (79% or 44 microRNAs) were repressed and only 12 low abundance 
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microRNAs were weakly induced during this time frame. Given the low basal 
expression levels of these induced microRNAs, we were unable to confirm their 
upregulation via quantitative PCR. Because microRNA expression levels can vary 
widely, we focused our efforts on the abundantly expressed, and thus potentially 
biologically active microRNAs (basal intensity values >200). Percent repression 
values (intensity glucocorticoid/intensity control) were generated for these 
microRNAs (Figure 2.2B). Interestingly, these abundantly expressed microRNAs 
were repressed uniformly irrespective of their genomic locations, suggesting that the 
repression of microRNA expression during glucocorticoid-induced apoptosis occurs 
post-transcriptionally, perhaps at the level of bioprocessing. The repression of a 
subset of microRNAs identified as differentially expressed (let-7a, miR-15b and miR-
25) as well as the repression of a microRNA not significantly regulated in the 
microarray (miR-17) was validated via quantitative PCR analysis (Figure 2.2C). 
Interestingly, the expression of miR-17 and let-7a primary transcripts was increased 
during glucocorticoid-induced apoptosis, providing important evidence that the 
repression of the resultant mature microRNAs occurs post-transcriptionally (Figure 
2.2D).  
In order to evaluate the expression of the microRNAnome during 
glucocorticoid-induced apoptosis using an alternative approach, we performed next 
generation sequencing, or deep sequencing of microRNAs from the control and 
glucocorticoid-treated samples. These samples were obtained from independent 
animals than those described in Figure 2.2, however these cells  exhibited apoptotic 
kinetics similar to those described in Figure 2.1. Deep sequencing of microRNAs is 
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an open-ended and hybridization-independent approach that facilitates the detection 
of both annotated and novel microRNAs. In our study, massively parallel sequencing 
of control and glucocorticoid treated RNA samples generated millions of short 
sequences (commonly referred to as ‘reads’), which were aligned to the reference 
rat genome (Figure 2.3A). We identified a set of 1782 sites (genomic loci that may 
be encoding microRNAs) that were down-regulated, and 238 sites that were 
upregulated by glucocorticoid treatment (see methods for more details). Of the 1782 
sites, 132 sites were within 100bp of an annotated microRNA, which correspond to 
129 individual microRNAs (Supplementary Table 2.1). It is also possible that the 
sites not immediately adjacent to a known microRNA may house novel microRNAs, 
which warrants further evaluation. Similar to the aforementioned microarray study, 
we detected a number of sites that were upregulated by glucocorticoid treatment; 
however, none of the 238 up-regulated sites were in close proximity to an annotated 
microRNA (Figure 2.3B). These results obtained by deep sequencing mirror the 
microarray findings of prevalent microRNA repression and minimal microRNA 
induction during glucocorticoid-induced apoptosis of primary thymocytes. In addition, 
the percent repression values of abundantly expressed microRNAs generated using 
deep sequencing data (Figure 2.3C) were comparable to those generated using 
microarray data (Figure 2.2B), further suggesting the post-transcriptional repression 
of microRNAs during glucocorticoid-induced apoptosis of lymphocytes. Deep 
sequencing analysis confirmed the repression of 35 of the 44 microRNAs repressed 
in the microarray analysis (79%). Moreover, microRNA deep sequencing was also 
able to detect repressed microRNAs not detected by microarray (representative 
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values in grey, Figure 2.3C), suggesting that deep sequencing of microRNAs is a 
more sensitive technique that may be used in conjunction with microRNA microarray 
and quantitative PCR as a novel “weight of evidence” approach to comprehensive 
profiling of the microRNAnome.  
MicroRNA processing enzymes are dysregulated during glucocorticoid-
induced apoptosis 
The broad, genome-wide downregulation of microRNA expression detected 
by both microarray and deep sequencing analysis and the absence of primary 
microRNA transcript repression suggests post-transcriptional repression of mature 
microRNAs during glucocorticoid-induced apoptosis of lymphocytes. To evaluate this 
hypothesis, we examined the expression of key microRNA processing enzymes, 
Drosha, DGCR8/Pasha and Dicer during glucocorticoid-induced apoptosis of 
primary thymocytes. Following 6 hours of glucocorticoid treatment, the mRNA 
expression of each processor is repressed, with the repression of Dicer and 
DGCR8/Pasha mRNA achieving statistical significance (Figure 2.4A). After 12 hours 
of treatment, the mRNA levels of each processor are significantly repressed in 
response to glucocorticoid-induced apoptosis (Figure 2.4A). The reduced expression 
of microRNA processing enzymes is not due to an apoptosis-related global increase 
in RNase activity since the expression of the glucocorticoid-responsive genes 
Gelsolin and Bim are strongly induced under these conditions in our cells (Figure 
2.4C).  
The repression of microRNA processing enzymes was also evident at the 
level of protein expression (Figure 2.4B). Drosha protein expression was decreased 
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following 6 hours of glucocorticoid treatment and was essentially undetectable at 12 
hours. The expression of Drosha’s cofactor DGCR8/Pasha was also reduced in 
response to glucocorticoid treatment and upon overexposure, potential cleavage 
products were detected following 12 hours of treatment. Furthermore, the protein 
expression of the cytoplasmic processor, Dicer, was also markedly reduced 
following 6 hours of glucocorticoid treatment, while at 12 hours full-length Dicer was 
nearly undetectable (Figure 2.4C).  
MicroRNA repression enhances glucocorticoid-induced apoptosis of 
lymphocytes 
To assess if the repression of microRNA expression contributes to the cell-
death process, we silenced the expression of Dicer, the enzyme responsible for 
mature microRNA biosynthesis, in two human lymphoid cell lines. The transition to 
cultured cell lines was necessary because primary rat thymocytes are difficult to 
genetically manipulate in-vitro. Therefore, we performed our functional analyses in 
the Jurkat GRα and the CEM-C7 leukemic cell lines. The Jurkat GRα cell line was 
generated by the exogenous overexpression of the full-length glucocorticoid receptor 
alpha (GRα) isoform in the glucocorticoid-resistant Jurkat ALL parental cell line (14) 
and stable overexpression of GRα restores glucocorticoid sensitivity to Jurkat cells 
(Figure 2.5A). The glucocorticoid-sensitive CEM-C7 cell line contains an 
endogenous, hormone responsive GRα and exhibits slower apoptotic kinetics in 
response to glucocorticoid compared to the Jurkat GRα cell line (Figure 2.5A). 
Interestingly, similar to the results obtained in primary cell culture, Dicer expression 
is repressed at both the mRNA and protein levels in each leukemic cell line during 
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glucocorticoid-induced apoptosis (Figure 2.5B). Stable Dicer depletion in these cells 
was achieved via lentiviral transduction of shRNA (Figure 2.5C) and the depletion of 
Dicer resulted in the reduced expression of a subset of microRNAs (Figure 2.5D). 
Dicer depletion and the subsequent repression of microRNA expression augmented 
glucocorticoid induced apoptosis in both cell lines as determined by flow cytometric 
evaluation of phosphatidylserine exposure and plasma membrane integrity (Figure 
2.5E). Importantly, this increased sensitivity to glucocorticoid-induced apoptosis was 
not due to increased GR expression in the absence of Dicer expression (data not 
shown). These data suggest that Dicer depletion and subsequent microRNA 
repression enhances the progression of glucocorticoid-induced apoptosis in 
lymphocytes. 
Overexpression of the repressed miR-17-92 polycistron blunts glucocorticoid-
induced apoptosis 
To delineate the potential role of specific microRNAs downregulated during 
glucocorticoid-induced apoptosis, we sought to overexpress the anti-apoptotic miR-
17-92 polycistron. Members of this polycistron were repressed by glucocorticoid 
treatment in primary thymocytes, as determined by both the microarray and deep 
sequencing studies. Furthermore, mature members of this polycistron are also 
downregulated during glucocorticoid induced apoptosis of cultured leukemic cells 
(Figure 2.6A). Overexpression of the microRNA 17-92 polycistron via lentiviral 
transduction of 17-92 precursor microRNA resulted in efficient overexpression of 
individual mature 17-92 polycistron members in the Jurkat GRα cell line (Figure 
2.6B). Overexpression of 17-92 polycistron members in the Jurkat GRα background 
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significantly diminished the ability of both sub-saturating and saturating doses of 
dexamethasone to induce glucocorticoid-induced apoptosis (Figure 2.6C). This 
diminished sensitivity was not due to decreased GR expression in response to miR-
17-92 overexpression (data not shown). In addition, primary thymocytes derived 
from mice transgenic for the 17-92 polycistron (approximately 1.5-2 fold 
overexpression of mature miR-17-92 polycistron members (8)) in the lymphocyte 
compartment exhibited decreased sensitivity to glucocorticoid-induced apoptosis 
(Figure 2.6D). This decreased sensitivity to glucocorticoid-induced apoptosis may 
also contribute to the hematomalignant phenotype of these mice. These data 
suggest that the specific repression of microRNA 17-92 polycistron contributes to 
glucocorticoid-induced apoptosis of lymphocytes in-vitro and in-vivo. 
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2.4 DISCUSSION 
Glucocorticoid-induced apoptosis is a key component of thymocyte 
development. Furthermore, owing to their potent apoptosis-inducing properties, 
synthetic glucocorticoids are common components of hematomalignant 
chemotherapy regimens. Here we provide evidence of broad microRNA repression 
during glucocorticoid-induced apoptosis of lymphocytes. This repression was 
associated with the dysregulation of both nuclear (Drosha and DGCR8/Pasha) and 
cytoplasmic (Dicer) microRNA processing enzymes and the increased expression of 
primary microRNA transcripts. It is possible that the dysregulation of the microRNA 
bioprocessing pathway results in the nuclear accumulation of un-processed primary 
microRNAs, accounting for the increased expression of microRNA primary 
transcripts observed during glucocorticoid-induced apoptosis. Dicer repression and 
cleavage during apoptosis has recently been reported in laboratory derived human 
endothelial cells, HL-60 leukemic cells and HeLa cervical carcinoma cells in 
response to various apoptotic stimuli (15-18). This dysregulation of Dicer protein 
expression has recently been attributed to caspase-3 cleavage (16). The precise 
mechanism of Dicer mRNA repression during apoptosis remains undetermined. 
Interestingly, we show that Dicer repression in response to glucocorticoid-induced 
apoptosis is conserved in both primary and transformed lymphocytes. Therefore, the 
results of this study expand our current understanding of Dicer repression in 
response to apoptotic stimulation while being the first to detail the dysregulation of 
all three key microRNA processing enzymes during glucocorticoid-induced apoptosis 
of lymphocytes. Additional studies in our laboratory have revealed that alternative 
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apoptotic stimuli, specifically Fas-ligand and UVC, also promote the repression of 
microRNA expression and processing enzymes during primary thymocyte apoptosis, 
suggesting that the dsyregulation of microRNA expression and bioprocessing 
machinery is a common convergence point for multiple apoptotic pathways during 
apoptosis of lymphocytes (Supplementary Figure 2.1). 
Several recent studies have suggested that sex steroid hormones also exert 
post-transcriptional control through the regulation of microRNA processing and 
expression. For example, ligand-bound estrogen receptor alpha (ERα) regulates 
microRNA expression in cultured MCF-7 breast cancer cells, myometrial and 
leiomyoma smooth muscle cells (MSMC and LSMC), rat mammary tissue, and 
mouse splenic lymphocytes (19-24). MicroRNAs can negatively regulate the ERα 
transcriptional response via translational inhibition of estrogen-responsive genes and 
the p160 transcriptional coactivator, AIB1 (20,21). Additionally, estrogen treatment of 
ovarectomized mice led to the repression of a subset of microRNAs (25). This study 
found that ligand-activated ERα inhibits Drosha processing of precursor microRNAs 
by mediating the dissociation of the Drosha microprocessor machinery from the 
precursor microRNA. These results provide additional mechanisms for hormonal 
impairment of microRNA processing. Alternatively, androgen treatment of androgen-
responsive prostate cancer cell lines induced the expression of 16 mature 
microRNAs in the absence of microRNA repression (26). Further analysis identified 
direct transcriptional activation of miR-21 via androgen receptor binding to the miR-
21 promoter region, indicating that nuclear hormone receptors can also act via 
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classical ligand-activated transcription factor signaling in order to induce microRNA 
expression.  
Previously, a single study sought to examine the expression of mature 
microRNAs during glucocorticoid-induced apoptosis of human lymphocytes. In 
conflict with our results, this group did not detect the prevalent repression of 
microRNAs in response to glucocorticoid treatment (27). Moreover, this study could 
not validate the downregulation of any microRNA repressed on their array via 
quantitative PCR and in contrast reported the induction of three microRNAs, miR-
15b, -16, and -223. Interestingly, in our model system we observe the strong 
repression of miR-15b in response to glucocorticoid-induced apoptosis (Figure 2c). 
These discrepancies are likely due to the use of alternative experimental models, 
different methods of data analysis, and distinct microarray platforms.  
Interestingly, the results of a separate analysis indicate that the hormonal regulation 
of microRNAs is likely specific to cell-type and physiological context. For example, 
glucocorticoid treatment of lung epithelial cells, which do not undergo glucocorticoid-
induced apoptosis, failed to significantly alter microRNA expression (28). These data 
suggest that the dramatic downregulation of microRNA expression reported in our 
study is likely due to the physiological activation of the apoptotic cascade in 
response to glucocorticoid treatment.  
We also report that the depletion of Dicer and Dicer-dependent microRNA 
expression enhanced glucocorticoid-induced apoptosis in two human leukemic cell 
lines. Dicer has an essential role in the development of the adaptive immune 
system. Conditional deletion of Dicer expression in the T-cell compartment results in 
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impaired T-cell development and diminished regulatory T-cell function (29-31) and 
ablation of Dicer expression in the B-cell compartment attenuates B-cell 
development and alters the antibody repertoire (32). Therefore, Dicer depletion 
hinders lymphocyte development and increases sensitivity to glucocorticoid-induced 
apoptosis.  
Furthermore, we detail that the overexpression of specific microRNAs 
repressed during glucocorticoid-induced apoptosis of lymphocytes, the microRNA 
17-92 polycistron, blunts glucocorticoid-induced apoptosis in both leukemic and 
primary lymphocytes. Interestingly, transgenic overexpression of the miR-17-92 
polycistron suppresses expression of the pro-apoptotic Bcl-2 family member, Bim 
(8). The induction of Bim expression is a critical component of glucocorticoid-
induced apoptosis signaling (33-36). Therefore, decreased basal Bim expression or 
weakened Bim induction upon glucocorticoid treatment may account for the 
decreased sensitivity of miR-17-92 overexpressing leukemic and primary 
lymphocytes to glucocorticoid-induced apoptosis.  
In summary, we have shown the prevalent repression of microRNAs during 
glucocorticoid-induced apoptosis of lymphocytes. This repression was associated 
with decreased expression of microRNA processing enzymes and increased primary 
microRNA transcript expression. Additionally, we observed the dysregulation of 
microRNA bioprocessing machinery in response to alternative apoptotic stimulation.  
Furthermore, depletion of the terminal processing enzyme responsible for the 
generation of mature, biologically active microRNAs, Dicer, resulted in increased 
sensitivity to glucocorticoid-induced apoptosis in human leukemic cell lines. Finally, 
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the in-vitro and in-vivo overexpression of microRNAs repressed during 
glucocorticoid-induced apoptosis, the miR-17-92 polycistron, hinders glucocorticoid-
induced apoptosis. These results suggest that the broad, post-transcriptional 
repression of microRNA processing and the specific repression of the microRNA 17-
92 polycistron act as modulators of glucocorticoid-induced apoptosis in both primary 
and cultured leukemic lymphocytes.  
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2.5 MATERIALS AND METHODS 
Rat Primary Thymocyte Isolation 
Rat primary thymoyctes were isolated from adrenalectomized male Sprague-Dawley 
rats (60-75g) approximately 1-2 weeks after surgery. Following decapitation, the 
thymi of three animals were removed and pooled in RPMI 1640 medium containing 
10% heat-inactivated fetal bovine serum, 4 mM glutamine, 75 units/ml streptomycin, 
and 100 units/ml penicillin. Thymi were gently sheared with surgical scissors at room 
temperature. Sheared cells were filtered through 200 micron nylon mesh twice and 
centrifuged at 3K for 5 minutes at room temperature. The cell pellet was then 
resuspended in fresh media and filtered into a sterile conical tube. Cells were 
cultured at a final concentration of 2x106 cells/mL and incubated at 37°C, 5% CO2 
atmosphere.  
Mouse Primary Thymocyte Isolation  
Primary thymocytes were isolated from adrenalectomized male B57BL/6 wild-type 
control or miR-17-92 transgenic mice at 20 weeks of age. Following cervical 
dislocation, individual thymi from eight animals were removed and gently sheared to 
dissociate free thymocytes. Sheared cells were then processed and cultured as 
described above. 
Human Cell Culture 
The Jurkat GRα cell line was kindly generated by Dr. Nick Lu in our laboratory. 
Briefly, parental Jurkat cells were transfected with pTRE hGRα vector (37) using the 
Lonza Nucleofector System (Basel, Switzerland). Stably overexpressing clones were 
established by hygromycin/G418 selective pressure (200ug/mL). CEM-C7 leukemic 
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cells were obtained from Dr. Carl Bortner. For all experiments, Jurkat GRα and 
CEM-C7 cells were cultured at a density of 2x105 cells/mL in RPMI 1640 medium 
containing 10% heat-inactivated fetal bovine serum, 4 mM glutamine, 75 units/ml 
streptomycin, and 100 units/ml penicillin 
Dicer Depleted Cells 
CEM-C7 and Jurkat GRα cells were transduced with lentivirus encoding Dicer 
shRNA or non-targeting control at a multiplicity of infection of 5. Stable Dicer 
depleted cells were established by puromycin selection (2ug/mL). Anti-Dicer and 
non-targeting control Mission shRNAs were purchased from Sigma Aldrich USA.  
MiR-17-92 Overexpressing Cells 
Jurkat GRα cells were transduced with lentivirus encoding miR-17-92 pre-miRNA or 
empty vector control at a multiplicity of infection of 10. Transduction at this 
multiplicity of infection resulted in a transduction efficiency of >90% as determined 
by CopGFP expression. Lenti-miR miR-17-92 precursor and empty vector clones 
were purchased from System Biosciences (Mountain View, CA). 
Lentivirus Generation 
All lentivirus were packaged in HEK293T cells according to established protocols 
(38). HEK293T cells were transiently transfected with pMD2G, psPAX2 and transfer 
vector containing the desired gene or miRNA using Lipofectamine 2000. 
Supernatant was collected 48 hours post-transfection and concentrated by 
centrifugation at 50,000xg for 2 hours. Pellets were resuspended in PBS and used 
for infection. All titers were determined by quantitative PCR analysis of lentiviral 
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integration into the host genome. In addition, titration of viruses co-expressing 
fluorescent moieties was determined by flow cytometric analysis.  
MicroRNA Microarray 
Rat primary thymocytes were isolated and cultured in the presence or absence of 
100nM dexamethasone for 6 hours. Following treatment, total RNA was isolated 
from untreated control and dexamethasone-treated samples and subjected to 
microarray analysis using Agilent Rat miRNA V2 (Design ID #019159) 8x15 
multiplex format arrays (Agilent Technologies) following the Agilent 1-color miRNA 
Complete Labeling and Hyb Kit protocol. Starting with 70-100ng of total RNA, the 
Cy3-pCp (Cytidine bisphosphate) reagent was used to selectively label mature 
miRNAs according to manufacturer’s protocol. In combination with the miRNA 
microarray probe design, the Cy3-pCp (Cytidine bisphosphate) reagent ensures 
detection of both low-abundance and highly homologous miRNAs.  Each labeled 
sample was hybridized for 20 hours in a rotating hybridization oven.  Slides were 
washed and then scanned with an Agilent Scanner.  Data was obtained using the 
Agilent Feature Extraction software (v9.5), using the miRNA defaults for all 
parameters.  The Agilent Feature Extraction Software performed error modeling, 
adjusting for additive and multiplicative noise.  The resulting data were processed 
using the Rosetta Resolver® system (version 7.2) (Rosetta Biosoftware, Kirkland, 
WA). Error-weighted ratios and the associated p-values were generated by Resolver 
in order to identify differentially expressed probes. The p-value p<0.05 was used to 
generate gene lists of differentially expressed microRNAs. 
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MicroRNA Deep Sequencing 
Rat primary thymocytes were isolated and cultured in the presence or absence of 
100nM dexamethasone for 6 hours. Following treatment, total RNA was isolated 
from untreated control and dexamethasone-treated samples and subjected to 
microRNA Deep Sequencing. Small RNA cDNA libraries were prepared according to 
manufacturer’s protocol (Small RNA Sample Prep Kit Oligo Only, protocol 71003, 
Illumina, Inc., San Diego, CA). Small RNA cDNA libraries were then sequenced 
according to manufacturer’s instructions on the Illumina Genome Analyzer II 
(Illumina, Inc., San Diego, CA). 
Bioinformatics 
Reads were aligned to the reference Rat genome (2004 assembly) using Bowtie 
(39). Given that mature microRNAs are usually around 18-20 nucleotides in length 
we used the first 20 nucleotides from the 5’ end of the read sequence for the 
alignment (to avoid the adapter sequence that may be present in the read 
sequence). We allowed up to two mismatches and up to three alignments of same 
quality per read sequence. Reads that aligned at more than three unique genomic 
locations were removed from further analysis to avoid repetitive elements. Fold 
changes were calculated as a ratio of total number of reads in the control divided by 
the total number of reads in dexamethasone treatment; as implemented in Erange 
(40) for sites that contained at least 20 aligned Reads in either of the two samples. 
Sites that were within 100bp of a previously annotated microRNA and displayed Fold 
change of 2.0 or greater in either direction were selected for detailed analyses. 
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Quantitative PCR Analysis 
Total RNAs were isolated using the Ambion mirVana miRNA isolation kit (Austin, 
TX). For mature microRNA and primary microRNA analysis, total RNAs were 
reverse transcribed using the Taqman microRNA Reverse Transcription kit and 
analyzed using Taqman mature microRNA and primary microRNA Assays (Applied 
Biosystems, CA, USA). For gene expression analysis, total RNAs were reverse 
transcribed using the Taqman Reverse Transcription kit and analyzed with Taqman 
Gene Expression Assays (Applied Biosystems, CA, USA). All quantitative PCR 
reactions were performed on a 7900HT Quantitative PCR platform (Applied 
Biosystems, CA, USA).  
Western Blotting and Antibodies 
Cells were harvested and lysed in 1X Laemelli Buffer containing 2.5% beta 
mercaptoethanol (BioRad, Hercules, CA). Whole cell lysates (20-30ug) were 
fractionated on 6% or 8% Tris-Glycine gels (Invitrogen) and transferred to 
nitrocellulose membranes. Membranes were probed overnight with the following 
antibodies: Dicer rabbit polyclonal, 1:200 (Santa Cruz Biotechnology, Santa Cruz, 
CA), Drosha rabbit polyclonal, 1:200 (Santa Cruz Biotechnology, Santa Cruz, CA), 
DGCR8/Pasha goat polyclonal, 1:1000 (Abnova, Taipei City, Taiwan), beta-actin, 
1:10,000 (Millipore, Billerica, MA). 
Alternative Apoptotic Stimuli 
Isolated primary thymocytes were treated with 25 ng/mL Fas-Ligand (Kamiya 
Biomedical, Seattle, WA) or 60 mJ/cm2 UVC using a UV lamp emitting at 254nm for 
60 seconds.  
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Apoptosis Assays 
Apoptosis was evaluated via Annexin V/Propidium Iodide staining or propidium 
iodide staining alone. For Annexin-V analysis, cells were stained with Annexin-V 
according to the manufacturer’s protocol and counterstained with propidium iodide 
(Trevigen, Gaithersburg, MD). Caspase-3 activation was monitored via CaspaTag 
fluorescence and cells were stained according to manufacturer’s instructions 
(Millipore, Billerica, MA). For propidium iodide staining alone, propidium iodide 
(Invitrogen) was added to achieve a final concentration of 10ug/mL. Following 
staining, cells were immediately analyzed on a Becton Dickinson FACSort cytometer 
equipped with CellQuest software. 
Animals 
Adrenalectomized miR-17-92 transgenic mice or C57BL/6 wild-type controls were 
obtained from Jackson Labs (Bar Harbor, ME). Adrenalectomized rats were obtained 
from Charles River Laboratories (Wilmington, MA). All experiments were performed 
in accordance the NIEHS Institutional Animal Care and Use Committee. 
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2.8 FIGURES 
Figure 2.1 Evaluation of glucocorticoid-induced apoptosis of primary 
thymocytes. Primary thymocytes were isolated and treated with 100nM 
dexamethasone for 0, 6 or 12 hours. Apoptotic progression was monitored via flow 
cytometric analysis of phosphatidylserine exposure, plasma membrane integrity and 
caspase-3 activation. (A) As cells undergo apoptosis the internal phosphatidylserine 
component of the plasma membrane becomes externalized. This increased 
externalization was detected via fluorescently labeled Annexin-V. Additionally, cells 
undergoing apoptosis exhibit a decrease in plasma membrane integrity. This loss of 
plasma membrane integrity was detected via the uptake of propidium iodide (PI) vital 
dye. Results are expressed as percent positive mean values +/-SEM for three 
independent experiments (*p<.05, **p<.01). (B). Apoptosis culminates in the 
activation of the effector caspase, caspase-3. Caspase-3 activation was monitored 
via the binding of fluorescently labeled CaspaTag to active caspase-3. Results are 
expressed as percent positive mean values +/-SEM for three independent 
experiments (***p<.001). 
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Figure 2.2 Repression of microRNA expression during glucocorticoid-induced 
apoptosis of primary thymocytes. Primary thymocytes were isolated and treated 
with 100nM dexamethasone for 6 hours. Total RNAs were subjected to microRNA 
microarray analysis on the Agilent rat genome microRNA array. (A) Heatmap 
representation of microRNAs significantly regulated in control and dexamethasone-
treated primary thymocytes, red indicates microRNAs induced by dexamethasone 
treatment, and green indicates microRNAs repressed (three independent biological 
replicates, p <.05).  (B) Percent repression of abundantly expressed microRNAs 
(basal intensity values>200). Values are calculated as intensity dexamethasone-
treated/intensity untreated. (C) Quantitative PCR validation of microRNA microarray. 
MicroRNA microarray results were validated by quantitative PCR analysis of three 
microRNAs significantly regulated on the array as well as one microRNA (miR-17) 
not significantly regulated. Results are expressed as percent of control mean values 
+/- SEM for three independent experiments (*p<.05). (D) Quantitative PCR analysis 
of primary microRNA expression. MiR-17 and let-7a primary microRNA transcript 
expression was analyzed via quantitative PCR and normalized to the GusB 
housekeeping gene. Results are expressed as percent of control mean values +/- 
SEM for three independent experiments. 
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Figure 2.3 MicroRNA deep sequencing confirms the prevalent repression of 
microRNA expression during glucocorticoid-induced apoptosis. Primary 
thymocytes were isolated and treated with 100nM dexamethasone for 6 hours. Total 
RNAs were subjected to microRNA deep sequencing analysis. (A) Deep sequencing 
of two biological replicates was performed using the Illumina Solexa platform for 
each treatment group and the resulting sequences from replicates were combined 
for further analyses. Sequences were aligned to the reference rat genome and sites 
that were enriched with reads were selected for further analysis. (B) Peak detection 
and ratio calculation revealed prevalent downregulation of microRNAs in response to 
dexamethasone treatment. Ratios were calculated as control vs. dex (microRNAs 
repressed) and dex vs. control (microRNAs induced). (C) Percent repression of 
abundantly expressed microRNAs correlates with microRNA microarray results. 
Values are calculated as intensity dexamethasone-treated/intensity untreated 
presented as percent of control. ND denotes microRNAs detected by microarray 
analysis but not deep sequencing analysis. MicroRNAs highlighted in gray indicate a 
subset of microRNAs repressed in deep sequencing analysis, but not microarray 
analysis. 
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Figure 2.4 MicroRNA processing enzymes are dysregulated during 
glucocorticoid-induced apoptosis of primary thymocytes. Primary thymocytes 
were isolated and treated with 100nM dexamethasone for 6 and 12 hours. (A) The 
mRNA expression of the microRNA processing enzymes Drosha, DGCR8/Pasha 
and Dicer was evaluated by quantitative PCR. Results are expressed as percent of 
control mean values +/- SEM for three independent experiments (*p<.01, **p<.001). 
(B) Whole cell lysates were immunoblotted with Drosha, DGCR8/Pasha or Dicer 
polyclonal antibodies. Actin immunoblotting served as a loading control and results 
are representative of at least three independent experiments. (C) Induction of Bim 
and Gelsolin mRNA expression during glucocorticoid-induced apoptosis. Primary 
thymocytes were isolated and treated with 100nM dexamethasone for 6 and 12 
hours. The mRNA expression of Bim and Gelsolin was evaluated by quantitative 
PCR. Results are expressed as percent of control mean values +/- SEM for three 
independent experiments (*p<.01, **p<. 001). 
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Figure 2.5 MicroRNA depletion contributes to glucocorticoid-induced 
apoptosis in human leukemic cell lines. (A) Flow cytometric analysis of 
glucocorticoid-induced apoptosis in Jurkat GRα and CEM-C7 ALL leukemic cell 
lines. Cells were treated with 100nM dexamethasone and apoptotic progression was 
monitored at 24,48 and 72 hours via flow cytometric analysis of propidium iodide 
uptake. Results are represented as mean percent PI positive values +/- SEM for 6 
independent experiments (*p<.01, **p<.001). (B) Repression of Dicer expression 
during glucocorticoid-induced apoptosis of human leukemic cell lines. Cells were 
treated with 100nM dexamethasone for 24 and 48 hours. The expression of Dicer 
mRNA was evaluated in total RNA via quantitative PCR. The expression of GusB 
mRNA served as an endogenous control. Results are represented as percent of 
control mean values +/- SEM for three independent experiments (*p<.01). Whole cell 
lysates were immunoblotted with Dicer polyclonal antibody. Actin immunoblotting 
served as a loading control. Results are representative of three independent 
experiments. (C) Stable silencing of Dicer protein expression in Jurkat GRα and 
CEM-C7 lymphocyte cell lines via lentiviral transduction of shRNA. Whole cell 
lysates from cells stably transduced with non-targeting control or anti-Dicer shRNA 
were immunoblotted with Dicer polyclonal antibody.  Results are representative of at 
least three independent experiments. (D) Repression of mature microRNA 
expression in the absence of Dicer expression. Total RNAs from non-targeting 
control and Dicer depleted cells were evaluated for the expression of three 
independent mature microRNAs via quantitative PCR. The expression of Rnu43 
small nuclear RNA served as an endogenous control. Results are reported as 
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percent of non-targeting control values +/- SEM for three independent experiments 
(*p<.05) (e) Enhancement of glucocorticoid-induced apoptosis in Dicer depleted 
cells. Flow cytometric analysis of Annexin-FITC and propidium iodide uptake in non-
targeting control and Dicer depleted stable cell lines in response to 48 hours of 
100nM dexamethasone treatment. Results were normalized to untreated control and 
values are representative of three independent experiments (*p<.05, **p<.01). 
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Figure 2.6 Overexpression of miR-17-92 blunts glucocorticoid-induced 
apoptosis. (A) Repression of miR-17-92 expression during glucocorticoid-induced 
apoptosis of Jurkat GRα cells. Jurkat GRα cells were treated with 100nM 
dexamethasone for 24 and 48 hours. The expression of individual mature 
microRNA-17-92 polycistron members was evaluated via quantitative PCR. The 
expression of Rnu43 small nuclear RNA served as an endogenous control. Results 
are represented as mean percent of control values +/- SEM for three independent 
experiments (*p<.05). (B) Efficient overexpression of individual polycistron members 
in Jurkat GRα cells via lentiviral transduction. Jurkat GRα cells were stably 
transduced with lentivirus encoding the miR-17-92 precursor microRNA or empty 
vector control. The overexpression of individual mature microRNA-17-92 polycistron 
members was evaluated via quantitative PCR. The expression of Rnu43 small 
nuclear RNA served as an endogenous control. Results are represented as mean 
percent of vector control values +/- SEM for three independent experiments (*p<.05, 
**p<.01). (C) MiR-17-92 overexpression blunts glucocorticoid-induced apoptosis. 
Flow cytometric analysis of propidium iodide uptake in empty vector or miR-17-92 
stable overexpressors in response to 10nM and 100nM dexamethasone treatment. 
Results were normalized to untreated control and values are representative of three 
independent experiments (*p<.01). (D) Transgenic miR-17-92 overexpression 
hinders glucocorticoid-induced apoptosis of primary thymocytes. Primary thymocytes 
were derived from wild-type control and miR-17-92 transgenic mice and treated with 
10nM and 100nM dexamethasone for 12 hours. Apoptosis was monitored by flow 
cytometric analysis of Annexin-FITC/propidium iodide staining. Results were 
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normalized to untreated control and values are representative of four independent 
experiments (*p<.05). 
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Supplementary Table 2.1 MicroRNA deep sequencing detects prevalent 
repression of microRNAs during glucocorticoid-induced apoptosis of 
lymphocytes. Values are calculated as intensity dexamethasone-treated/intensity 
untreated and presented as percent of control for two independent biological 
replicates.  
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Supplementary Figure 2.1 Induction of apoptosis via alternative apoptotic 
stimuli also promotes the dysregulation of mature microRNA expression and 
bioprocessing. (A) Flow cytometric analysis of Fas-ligand and UVC-induced 
apoptosis of primary thymocytes. Primary thymocytes were treated with 25ng/mL 
Fas-ligand or 60mJ/cm2 for 0, 6 and 12 hours. Apoptosis progression was monitored 
via flow cytometric analysis of Annexin-FITC, propidium iodide, and CaspaTag 
staining. Results are expressed as percent positive +/- SEM for three independent 
experiments (*p<.05, **p<.01, ***p<.001). (B) Quantitative PCR analysis of mature 
microRNA expression during Fas-ligand and UVC-induced apoptosis of primary 
thymocytes. Following 6 and 12 hours of treatment, total RNAs were isolated and 
subjected to quantitative PCR analysis of mature microRNAs -15b, -17, and let-7a 
expression. Values are normalized to small nuclear RNA U87 and expressed as 
percent of control values for three independent experiments (*p<.05, **p<.01). (C) 
Western blot analysis of microRNA bioprocessor protein expression during Fas-
ligand and UVC-induced apoptosis of primary thymocytes. Following 6 and 12 hours 
of treatment, whole cell lysates were harvested and subjected to western blot 
analysis of Dicer, Drosha and DGCR8 expression. Actin immunoblotting served as a 
loading control and results are representative of three independent experiments.  
(D) Quantitative PCR analysis of microRNA bioprocessor mRNA expression during 
Fas-ligand and UVC-induced apoptosis of primary thymocytes. Following 6 and 12 
hours of treatment, total RNAs were isolated and subjected to quantitative PCR 
analysis of Dicer, Drosha and DGCR8 expression. Values are normalized to the 
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GusB housekeeping gene and expressed as percent control +/- SEM for three 
independent experiments (*p<.01). 
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APPENDIX 1 
 
 
 
DICER OVEREXPRESSION BLUNTS GLUCOCORTICOID-
INDUCED APOPTOSIS IN HUMAN LEUKEMIC CELL LINES 
AND DIMINISHES GLUCOCORTICOID RECEPTOR 
EXPRESSION IN A POST-TRANSCRIPTIONAL MANNER 
 
A1.1 ABSTRACT 
In continuation of our studies elucidating the role of microRNA dowregulation in the 
progression of glucocorticoid-induced apoptosis, we overexpressed the key mature 
microRNA biosynthetic enzyme, Dicer, in two glucocorticoid-sensitive human 
leukemic cell lines. Here, we report that Dicer overexpression significantly blunted 
glucocorticoid-induced apoptosis in both cell lines. Mechanistic studies of these 
Dicer-overexpressing human leukemic cell lines revealed a marked repression of 
glucocorticoid receptor (GR) protein while the expression of GR mRNA was 
unaffected. We further identified that 5 microRNAs predicted to target the GR 3’UTR 
were moderately upregulated in Dicer-overexpressing cells, suggesting a possible 
mechanism of Dicer-induced downregulation of GR protein expression in 
glucocorticoid-sensitive leukemic cells. 
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A1. 2 RESULTS 
Dicer overexpression blunts glucocorticoid-induced apoptosis 
To further delineate the role of Dicer in the progression of glucocorticoid-
induced apoptosis, we exogenously overexpressed full-length Dicer via lentiviral 
transduction in the glucocorticoid-sensitive Jurkat GRα and CEM-C7 cell lines, 
resulting in 2-fold overexpression of Dicer protein (Figure A1.1A). This Dicer 
overexpression significantly blunted glucocorticoid-induced apoptosis in response to 
both sub-saturating and saturating doses of glucocorticoid in the Jurkat GRα cell line 
(Figure A1.1B, top). This diminished apoptosis was also evident in Dicer-
overexpressing CEM-C7 cells in response to glucocorticoid treatment, suggesting 
that Dicer overexpression blunts the progression of glucocorticoid-induced apoptosis 
in glucocorticoid-sensitive leukemic cells (Figure A1.1B, bottom).  
Dicer overexpression diminishes glucocorticoid receptor expression in a post-
transcriptional manner 
To elucidate the potential mechanism of this blunted apoptotic response, we 
examined the expression of the GR under conditions of stable Dicer overexpression 
in these two human leukemic cell lines. Interestingly, stable Dicer overexpression 
resulted in the ~40% reduction of GR protein expression in each cell line (Figure 
A1.1C). This reduced expression of GR under conditions of Dicer overexpression is 
a lymphocyte-specific phenomenon, as the stable overexpression of Dicer protein 
(~2-fold) in the A549 lung adenocarcinoma cell line did not effect GR protein 
expression (Figure A1.1C). Furthermore, in all three cell lines, the stable 
overexpression of Dicer did not affect the expression of GR mRNA, suggesting that 
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GR downregulation under conditions of Dicer overexpression is occurring in a post-
transcriptional manner, perhaps through the upregulation of microRNAs specifically 
targeting GR (Figure A1.1D). To date, only two microRNAs, miR-18a and miR-124a 
have been experimentally validated as GR-targeting microRNAs, however this 
regulation was in neuronal cells (1). The microRNAs regulating GR expression in 
lymphocytes remain unknown.  
MicroRNAs predicted to target GR are upregulated in stable Dicer 
overexpressing cells 
MicroRNAs predicted to target the GR 3’UTR were computationally predicted 
using the TargetScanHuman microRNA target prediction algorithm (2). We selected 
5 microRNAs for further analysis: miR-18a, miR-124a, miR-204, miR-1284 and miR-
1303 (Figure A1.1E). Of these, miR-18a, miR-124a, and miR-204 are highly 
conserved among mammals and their predicted binding sites are also highly 
conserved. Conversely, miR-1284 and miR-1303 are human-specific and their 
predicted binding sites are poorly conserved. MicroRNAs depicted in blue (Figure 
A1.1E) target 8mer sites within the GR 3’UTR. These sites are an exact match to 
positions 2-8 of the mature microRNA (followed by an “A” residue) and are high 
probability binding sites. MicroRNAs depicted in pink (Figure A1.1E) target 7mer-m8 
sites, denoting an exact match to positions 2-8 of the mature microRNA. These sites 
are intermediate probability binding sites. Finally, microRNAs depicted in purple 
(Figure 1A.1E) target 7mer-1A sites, denoting an exact match to positions 2-7 of the 
mature microRNA followed by an “A” residue. These sites are the lowest probability 
binding sites.  
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Quantitative PCR analysis of each of these predicted GR-targeting 
microRNAs in the Dicer-overexpressing Jurkat GRα cells detected the modest 
induction of each of these microRNAs, with miR-1284 being significantly upregulated 
and miR-204 and miR-1303 exhibiting higher, but more variable levels of induction 
under conditions of Dicer overexpression. In rare cases, the action of a single highly 
complementary microRNA can act alone to repress a target mRNA. However, in 
mammals, microRNAs commonly act in a cooperative mechanism, targeting multiple 
sites within the target message, thereby eliciting translational repression (3). It is 
possible that the mild induction of GR-targeting microRNAs under conditions of Dicer 
overexpression may encourage the cooperative action of each of these microRNAs 
on the GR mRNA to enact translational repression, however this hypothesis remains 
untested at this time.  
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A1.3 MATERIALS AND METHODS 
Dicer Overexpressing Cells 
Jurkat GRα, CEM-C7, and A549 human cell lines were transduced with lentivirus 
encoding full-length human Dicer or empty vector control at multiplicity of infection of 
10, 50, and 20 respectively. Stably overexpressing cells were established by 
puromycin selection (2ug/mL). Dicer-Puro and empty vector clones were purchased 
from System Biosciences (Mountain View, CA). 
Apoptosis Assays 
Apoptosis was evaluated via Annexin-V/Propidium Iodide staining. For Annexin-V 
analysis, cells were stained with Annexin-V according to the manufacturer’s protocol 
and counterstained with propidium iodide (Trevigen, Gaithersburg, MD). Following 
staining, cells were immediately analyzed on a Becton Dickinson FACSort cytometer 
equipped with CellQuest software. 
Western Blotting 
 Cells were harvested and lysed in 1X Laemelli Buffer containing 2.5% beta 
mercaptoethanol (BioRad, Hercules, CA). Whole cell lysates (20-30ug) were 
fractionated on 6% Tris-Glycine gels (Invitrogen) and transferred to nitrocellulose 
membranes. Membranes were probed overnight with the following antibodies: Dicer 
rabbit polyclonal, 1:200 (Santa Cruz Biotechnology, Santa Cruz, CA), beta-Actin, 
1:10,000 (Millipore, Billerica, MA). 
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 Quantitative PCR 
For gene expression analysis, total RNAs were reverse transcribed using the 
Taqman Reverse Transcription kit and analyzed with Taqman Gene Expression 
Assays (Applied Biosystems, CA, USA). Total RNAs were isolated using the Ambion 
mirVana miRNA isolation kit (Austin, TX). For microRNA analysis, total RNAs were 
reverse transcribed using the Taqman microRNA Reverse Transcription kit and 
analyzed using Taqman microRNA Assays (Applied Biosystems, CA, USA). All 
quantitative PCR reactions were performed on a 7900HT Real-Time PCR platform 
(Applied Biosystems, CA, USA).  
MicroRNA Target Prediction 
MicroRNAs targeting the glucocorticoid receptor mRNA (NR3C1) 3’UTR were 
identified via the TargetScanHuman5.1 prediction of microRNA targets algorithm (2).  
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A1.6 FIGURES  
Figure 1. Dicer overexpression blunts glucocorticoid-induced apoptosis in 
human leukemic cell lines and diminishes glucocorticoid receptor expression 
in a post-transcriptional manner. (A) Evaluation of stable Dicer overexpression in 
the Jurkat GRα and CEM-C7 cell lines. Whole cell lysates were immunoblotted with 
Dicer polyclonal antibody. Actin immunoblotting served as a loading control and 
results are representative of at least three independent experiments. (B) Flow 
cytometric analysis of glucocorticoid-induced apoptosis in Dicer-overexpressing 
Jurkat GRα and CEM-C7 leukemic cell lines. Jurkat GRα cells stably overexpressing 
Dicer or empty vector control were treated with 10nM or 100nM dexamethasone and 
apoptotic progression was monitored at 24, 48 and 72 hours via flow cytometric 
analysis of Annexin-V/Propidium Iodide uptake. Results are represented as mean 
percent Annexin/PI positive values +/- SEM for 6 independent experiments (*p<.05, 
**p<.01, ***p<.001). CEM-C7 cells stably overexpressing Dicer or empty vector 
control were treated with 100nM dexamethasone and apoptotic progression was 
monitored at 72 hours via flow cytometric analysis of Annexin-V/Propidium Iodide 
uptake. Results are represented as mean percent Annexin/PI positive values +/- 
SEM for 3 independent experiments (*p<.05). (C) Analysis of glucocorticoid-receptor 
protein expression in Dicer-overexpressing Jurkat GRα, CEM-C7, and A549 cell 
lines. Whole cell lysates were immunoblotted with Dicer polyclonal antibody. Actin 
immunoblotting served as a loading control. Band intensities were quantified using 
Image J software and results are representative of at least three independent 
experiments. (d) Evaluation of GR mRNA expression in Dicer-overexpressing Jurkat 
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GRα, CEM-C7, and A549 cell lines. Dicer mRNA expression was analyzed via 
quantitative PCR and normalized to the Cyclophilin B housekeeping gene. Values 
are expressed as percent of control mean values +/- SEM for three independent 
experiments. (E) Prediction of microRNAs targeting the glucocorticoid receptor. 
Glucocorticoid-receptor targeting microRNAs were identified via the 
TargetScanHuman5.1 microRNA target prediction algorithm. MicroRNAs depicted in 
blue denote 8mer binding sites. MicroRNAs depicted in red denote 7mer-m8 binding 
sites and microRNAs depicted in purple denote 7mer-1A binding sites. (F) 
Evaluation of microRNAs predicted to target the glucocorticoid receptor. The 
expression of individual predicted mature microRNAs was evaluated in Jurkat GRα 
Dicer-overexpressing cells via quantitative PCR. The expression of Rnu43 small 
nuclear RNA served as an endogenous control. Results are represented as mean 
percent of control values +/- SEM for four independent experiments (*p<.05). 
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CHAPTER 3 
 
 
 
MICRORNA EXPRESSION DURING GLUCOCORTICOID-
INDUCED AND SPONTANEOUS THYMOCYTE APOPTOSIS 
 
 
 
 
 
 
3.1 ABSTRACT 
Apoptosis of immature thymocytes is a carefully coordinated process controlled by 
the actions of pro-apoptotic and anti-apoptotic effectors. Endogenous glucocorticoids 
are key regulators of immune development through the induction of apoptosis during 
T-cell selection. However, the stochastic nature of glucocorticoid-induced apoptosis 
complicates gene expression analysis. Here, we describe a novel, size-based, cell 
sorting approach to isolate only primary thymocytes actively engaged in 
glucocorticoid-induced or spontaneous (growth factor withdrawal-induced) 
apoptosis. MicroRNA microarray analysis of glucocorticoid-induced and 
spontaneously apoptotic sub-populations confirmed the prevalent downregulation of 
microRNAs during thymocyte apoptosis irrespective of the cell death stimuli. 
Interestingly, this analysis also identified the novel induction of miR-223 and miR-
451 in these apoptotic thymocyte sub-populations. The increased expression of 
these microRNAs was validated in primary thymocyte apoptotic sub-populations and 
in two glucocorticoid-sensitive human leukemic cell lines. This induction occurred 
under conditions of ongoing Dicer depletion in both glucocorticoid-induced and 
spontaneously apoptotic primary thymocyte sub-populations. Interestingly, the 
expression of miR-223 was refractory to stable Dicer silencing in glucocorticoid-
sensitive human leukemic cell lines and inhibition of miR-223 activity in these human 
leukemic cell lines significantly enhanced glucocorticoid-induced apoptosis. 
Alternatively, overexpression of miR-223 did not enhance glucocorticoid-induced 
apoptosis, suggesting an anti-apoptotic role for this microRNA in leukemic cells. 
140
3.2 INTRODUCTION 
Endogenous glucocorticoids are critical regulators of immune development 
during T-cell selection through the apoptotic elimination of undesirable immature 
thymocytes (1). Glucocorticoid-induced apoptosis of primary thymocytes is 
characterized by an early loss of cell volume resulting in rapid cell shrinkage (2). 
This shrinkage is due to an efflux of intracellular potassium (K+) accompanied by a 
loss of cellular water (2). Changes in the plasma membrane including phosphatidyl-
serine exposure and membrane blebbing are also early events in glucocorticoid-
induced apoptosis of thymocytes (3); while chromatin condensation, DNA 
fragmentation, caspase activation, and the loss of mitochondrial membrane potential 
all occur later in the apoptotic cascade (4-7). This cascade of events culminates in 
the disintegration of the cell and the formation of “apoptotic bodies” which are 
eliminated via phagocytosis, preventing the release of caustic intracellular contents 
into the intercellular environment (8,9). This coordinated cascade of biochemical and 
morphological changes is a conserved feature of apoptosis and has been observed 
in response to divergent apoptotic stimuli in a myriad of cell types, indicating that 
apoptotic signaling pathways reach a convergence point downstream of the initial 
apoptotic signal. For example, primary thymocytes placed in culture will undergo a 
degree of spontaneous apoptosis due to survival-factor deprivation (7). This 
spontaneous apoptosis bears the same morphological and biochemical 
characteristics of glucocorticoid-induced apoptosis; however, unlike glucocorticoid-
apoptosis, spontaneous apoptosis is not dependent upon de-novo gene expression. 
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This finding suggests that the glucocorticoid-induced and spontaneous apoptotic 
programs likely exhibit unique gene expression profiles (7).  
 In previous studies, we profiled the changes in microRNA expression during 
glucocorticoid-induced apoptosis. MicroRNAs influence numerous fundamental 
biological processes and have been identified as key effectors of lymphocyte 
function and apoptosis. Our studies revealed that glucocorticoids induce a prevalent 
downregulation of microRNA expression that contributes to the progression of 
apoptosis in these cells. However, glucocorticoid-induced apoptosis of primary 
thymocytes is a stochastic, asynchronous process with only a portion of cells 
displaying the morphological and biochemical characteristic of apoptosis at any 
given time. This asynchrony complicates the study of gene expression during 
apoptosis as these studies are commonly carried out on the entire cell population, 
regardless of where these cells are in the apoptotic process. This study of 
heterogeneous cell populations averages the different sub-populations and likely 
obscures the precise changes in gene expression occurring during apoptosis. To 
accurately profile microRNA expression during glucocorticoid-induced and 
spontaneous apoptosis of primary thymocytes, we have separated cells undergoing 
each apoptotic process into two distinct apoptotic sub-populations based on cell 
shrinkage, an early indicator of apoptosis. These populations of shrunken (apoptotic) 
and non-shrunken (viable) cells were then subjected to microRNA microarray 
analysis. We also observed a prevalent downregulation of microRNAs and the 
microRNA-processing enzyme, Dicer, during both glucocorticoid-induced and 
spontaneous apoptosis. However, by separating apoptotic cells from viable cells, we 
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also observed the significant induction of a subset of microRNAs in the apoptotic 
fractions derived from both glucocorticoid-induced and spontaneous pathways. 
Here, we describe a novel analysis of gene expression, specifically microRNA 
expression, in cells displaying the distinct morphological characteristics of apoptosis. 
Our findings reveal the specific regulation of microRNAs in these apoptotic sub-
populations.   
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3.3 RESULTS 
Primary thymocytes undergoing glucocorticoid-induced apoptosis or 
spontaneous apoptosis segregate into distinct cell-size sub-populations 
 Cell shrinkage due to volume loss is a hallmark of early apoptosis. To narrow 
the focus of our study to only those cells actively undergoing apoptosis, we 
employed a cell-size based, flow cytometry-assisted, cell sorting approach. Primary 
thymocytes actively undergoing apoptosis exhibit dramatic cell shrinkage due to 
volume loss. This decrease in cell size is monitored via flow cytometric analysis of 
forward and side light scattering properties. Cell shrinkage during early apoptosis is 
detected as a decrease in forward light scatter. As apoptosis advances, cellular 
granularity increases resulting in an increase in side scatter. Following isolation, 
untreated control cells were placed on ice to arrest cell shrinkage and apoptosis 
(Figure 3.1, top). These cells were then utilized as a template for the design of a cell-
size based gating strategy. Cells depicted in red (Figure 3.1) occupy the non-
shrunken gate and are “non-apoptotic” cells. Cells depicted in green occupy the 
shrunken gate and are deemed “apoptotic” cells. Primary thymocytes placed in 
culture will undergo a degree of apoptosis due to survival-factor withdrawal; 
therefore the shrunken fraction of these cells is undergoing “spontaneous” apoptosis 
(Figure 3.1, middle). Cells treated with glucocorticoids undergo apoptosis at an 
accelerated rate; therefore at six hours following treatment, the number of cells 
occupying the shrunken gate is increased when compared to untreated controls 
(Figure 3.1, bottom). Using this gating strategy, cell populations of both untreated 
control and glucocorticoid-treated primary thymocytes were sorted into distinct 
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shrunken (apoptotic) and non-shrunken (non-apoptotic) sub-populations (collecting 
1x107 cells/population). These four populations (spontaneous shrunken/apoptotic, 
control non-shrunken/non-apoptotic, dex shrunken/apoptotic, dex non-shrunken/non-
apoptotic) were then subjected to microRNA microarray analysis. 
MicroRNA microarray analysis of apoptotic and viable sub-populations 
demonstrates the prevalent repression of microRNA expression and the novel 
induction of microRNAs during both spontaneous and glucocorticoid-induced 
apoptosis of primary thymocytes 
 Following sorting, total RNAs obtained from apoptotic and non-apoptotic cell 
populations were subjected to microRNA microarray analysis to profile the 
microRNAnome during glucocorticoid-induced apoptosis and spontaneous apoptosis 
of primary thymocytes. Microarray analysis revealed the prevalent downregulation of 
microRNAs during both spontaneous and glucocorticoid-induced apoptosis. For 
example, 101 microRNAs were differentially expressed in the spontaneously 
apoptotic population when compared to the corresponding viable control population. 
Of these, 84 microRNAs (85%) were repressed (Figure 3.2A). Additionally, 82 
microRNAs were differentially expressed in the glucocorticoid-induced apoptotic 
population when compared to the corresponding viable control population. Of these, 
63 microRNAs (78%) were repressed (Figure 3.2A). Interestingly, we also observed 
a small number of unique microRNAs that were induced in the apoptotic population 
during both glucocorticoid-induced and spontaneous apoptosis. Specifically, 15 
microRNAs (15%) were upregulated during spontaneous apoptosis and 18 
microRNAs (22%) were upregulated during glucocorticoid-induced apoptosis (Figure 
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3.2A). Given the novelty of this finding, we first sought to identify induced 
microRNAs that may specifically modulate glucocorticoid-induced apoptosis. 
Utilizing Venn diagram analysis, we identified 31 microRNAs unique to 
glucocorticoid-induced apoptosis, 50 microRNAs unique to spontaneous apoptosis, 
and 51 microRNAs common to both pathways (Figure 3.2B).  MicroRNAs unique to 
glucocorticoid-induced apoptosis were evenly distributed among induced and 
repressed expression. However, most of the induced microRNAs exhibited 
extremely low basal expression levels (intensity value <20) and we were unable to 
confirm their induction via quantitative PCR. We next sought to determine whether 
the induced microRNAs shared by both the glucocorticoid-induced and spontaneous 
apoptosis pathways may contribute to conserved apoptotic signaling. This evaluation 
identified 3 microRNAs induced in both pathways, and two of these microRNAs, 
miR-451 and miR-223, exhibited sufficient basal expression levels for further study 
(Figure 3.2B). 
Quantitative PCR analysis confirms the altered expression of microRNAs 
during glucocorticoid-induced and spontaneous apoptosis of primary 
thymocytes  
Apoptotic and viable populations undergoing glucocorticoid-induced or 
spontaneous apoptosis were isolated via our sorting strategy and the resultant total 
RNAs were utilized for quantitative PCR validation of the microRNA microarray 
analysis. This analysis confirmed the induction of miR-451 and miR-223 in cells 
undergoing spontaneous apoptosis and the significant induction of miR-451 and 
miR-223 in cells undergoing glucocorticoid-induced apoptosis (Figure 3.3A). 
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Conversely, the significant repression of microRNAs -7a, -15b and -17 during both 
apoptotic programs was confirmed via quantitative PCR (Figure 3.3B).  
The induction of miR-223 is refractory to Dicer loss during glucocorticoid-
induced and spontaneous apoptosis 
We observed the pronounced repression of Dicer protein expression in 
apoptotic sub-populations isolated from thymocyte populations undergoing 
glucocorticoid-induced or spontaneous apoptosis, indicating the microRNAs induced 
in these sub-populations are refractory to the loss of Dicer expression (Figure 3.4A). 
Stable depletion of Dicer expression in two glucocorticoid-sensitive human leukemic 
cell lines (Figure 3.4B, top), which resulted in ~50% depletion of a subset of 
microRNAs (Figure 2.5D) did not reduce in the expression of miR-223. In fact, Dicer 
depletion significantly increased the expression of miR-223 in both cell lines (Figure 
3.4B, bottom). These results strongly suggest that the induction of miR-223 during 
glucocorticoid-induced and spontaneous apoptosis is occurring in a novel Dicer-
independent manner.  
Inhibition of miR-223 enhances glucocorticoid-induced apoptosis in 
glucocorticoid-sensitive human lymphoid cell lines 
To examine whether miR-223 induction modulates glucocorticoid-induced 
apoptosis, we overexpressed and inhibited miR-223 in these two glucocorticoid-
sensitive human leukemic cell lines. MiR-223 expression is significantly induced 
during glucocorticoid-induced apoptosis in both cell lines in a time dependant 
manner (Figure 3.5A). Utilizing a lentiviral approach, we stably overexpressed miR-
223 and inhibited miR-223 activity in both cells lines. This stable transduction of 
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miR-223 resulted in ~5 fold and ~3-fold overexpression in the Jurkat GRα and CEM-
C7 cell lines, respectively (Figure 3.5B). The stable and efficient overexpression of 
miR-223-targeting antisense RNA (223-ZIP) was confirmed via quantitative PCR 
(Supplementary Figure 3.1). Interestingly, miR-223 overexpression did not alter the 
kinetics of glucocorticoid-induced apoptosis in either cell system, while miR-223 
inhibition significantly enhanced glucocorticoid-induced apoptosis in the Jurkat GRα 
cell line (Figure 3.5C). This enhanced apoptosis was also evident in miR-223 
inhibited CEM-C7 cells in response to glucocorticoid treatment (Figure 3.5C). This 
enhanced apoptosis was not due to a miR-223 inhibition-mediated increase in GR 
expression (data not shown), suggesting that in these transformed human leukemic 
cell lines, miR-223 may act as an anti-apoptotic effector.  
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3.4 DISCUSSION 
 Historically, the evaluation of gene expression during apoptosis has been 
complicated by the stochastic nature of apoptosis. To bypass these complications 
we have devised a size-based cell sorting approach to isolate cells actively 
undergoing glucocorticoid-induced and spontaneous apoptosis from heterogeneous 
cell populations. MicroRNA microarray evaluation of these apoptotic populations 
confirmed our previous observation of prevalent downregulation of microRNAs 
during glucocorticoid-induced apoptosis as well as spontaneous apoptosis. 
However, for the first time, we also identified a novel subset of microRNAs induced 
in apoptotic populations derived from primary thymocytes engaged in both apoptotic 
programs. There is sufficient evidence suggesting that two members of this induced 
subset common to both pathways, miR-223 and miR-451, may modulate apoptosis. 
For example, miR-451 is downregulated in a number of cancers including gastric 
and colorectal tumors (10), ALL (11), and lung cancer (12). Furthermore, 
overexpression of miR-451 in MCF-7 breast cancer cells sensitized these cells to 
doxorubicin-induced apoptosis (13). Additionally, miR-223 is downregulated in AML 
(11), CLL (14), ALL (11), and hepatocellular carcinoma (15). However, miR-223 is 
also upregulated in numerous solid tumors including bladder (16), colorectal (17), 
esophageal (18), pancreatic (17), and prostate (17), indicating that the role of miR-
223 in apoptosis may be cell or tissue type-specific.  
 Interestingly, we observed the induction of miR-223 and miR-451 during both 
glucocorticoid-induced and spontaneous thymocyte apoptosis under conditions of 
Dicer depletion. Dicer is the central enzyme responsible for mature microRNA 
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biogenesis (19). The loss of Dicer expression during glucocorticoid-induced and 
spontaneous apoptosis correlates with the prevalent repression of microRNA 
expression during glucocorticoid-induced apoptosis. However, stable Dicer depletion 
in two glucocorticoid-sensitive human leukemic cell lines, which in our previous 
studies resulted in ~50% repression of representative microRNAs, did not repress 
miR-223 expression. In fact, miR-223 expression was significantly increased under 
conditions of Dicer-deficiency. A recent study of Dicer loss-of-function mouse 
embryos identified microRNAs refractory to Dicer-deficiency, including miR-451, one 
of the microRNAs induced during both glucocorticoid-induced and spontaneous 
apoptosis of primary thymocytes (20). Under conditions of Dicer depletion, miR-451 
expression is actually increased, corresponding to our finding of increased miR-223 
expression in the absence of Dicer expression (20). This study identified a novel 
Dicer-independent microRNA biosynthetic pathway that requires the catalytic activity 
of Argonaute2 (Ago2), a core member of the microRNA induced silencing complex 
(miRISC). Whether a microRNA will proceed down the Dicer-dependent or Ago2-
dependent biosynthetic pathway is largely determined by the secondary structure of 
the pre-mRNA (20). The involvement this novel Ago2-dependent pathway in miR-
223 bioprocessing requires further investigation.  
 Finally, miR-223 induction during both glucocorticoid-induced and 
spontaneous apoptosis of primary thymocytes suggests a pro-apoptotic role for this 
microRNA. However, ectopic overexpression of miR-223 in two glucocorticoid-
sensitive human leukemic cell lines had no effect on the progression of 
glucocorticoid-induced apoptosis, while inhibition of miR-223 enhanced 
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glucocorticoid-induced apoptosis in both cell lines, suggesting an anti-apoptotic role 
for miR-223 in leukemic cell lines. In agreement with our study, a previous study 
employing miR-223 overexpression and repression in an acute promyelocytic cell 
line reported that miR-223 overexpression enhanced proliferation and blunted 
apoptosis while miR-223 repression inhibited proliferation in these cells (21). 
However, an alternative analysis of granulocyte-specific miR-233-deficient mice 
described a phenotype characterized by increased granulocyte proliferation and 
reduced apoptosis, implying a pro-apoptotic role for this microRNA in developing 
granulocytes (22). These results indicate that the apoptotic function of miR-223 may 
vary during development. In summary, we have reported the induction of a subset 
of microRNAs in primary thymocytes undergoing glucocorticoid-induced and 
spontaneous apoptosis. This induction was also observed in two human leukemic 
cells lines undergoing glucocorticoid-induced apoptosis. Furthermore, the induced 
microRNA miR-223 is refractory to Dicer depletion during apoptosis, suggesting this 
microRNA may be processed by a novel microRNA biosynthetic pathway. Finally, 
specific inhibition of miR-223 activity enhanced glucocorticoid-induced apoptosis in 
two glucocorticoid-sensitive cell lines, suggesting that in leukemic cells miR-223 acts 
as an anti-apoptotic effector, while in primary thymocytes miR-223 may regulate 
apoptosis in an alternative manner.  
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3.5 MATERIALS AND METHODS 
Primary Thymocyte Isolation 
Rat primary thymoyctes were isolated from adrenalectomized male Sprague-Dawley 
rats (60-75g) approximately 1-2 weeks after surgery. Following decapitation, the 
thymi of three animals were removed and pooled in RPMI 1640 medium containing 
10% heat-inactivated fetal bovine serum, 4 mM glutamine, 75 units/ml streptomycin, 
and 100 units/ml penicillin. Thymi were gently sheared with surgical scissors at room 
temperature. Sheared cells were filtered through 200 micron nylon mesh twice and 
centrifuged at 3K for 5 minutes at room temperature. The cell pellet was then 
resuspended in fresh media and filtered into a sterile conical tube. Cells were 
cultured at a final concentration of 2x106 cells/mL and incubated at 37°C, 5% CO2 
atmosphere.  
Apoptotic Cell Sorting 
Isolation of apoptotic cells from primary rat thymocytes was achieved using a 
FACSVantage SE flow cytometer equipped with digital electronics (Becton 
Dickinson, San Jose, CA). All samples were excited at a 488 nm and primary sorting 
gates for the viable and apoptotic populations were set on a forward-scatter versus 
side-scatter dot plot. Propidium Iodide (PI, Ex 488/Em 585) was used to monitor cell 
membrane integrity. For analysis, ten thousand cells were examined per sample and 
analyzed using BD FACSDiVA software. 
MicroRNA Microarray 
Gene expression analysis was conducted using Agilent Rat miRNA V2 (Design 
 ID #019159) 8x15 multiplex format arrays (Agilent Technologies) following the 
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Agilent 1-color miRNA Complete Labeling and Hyb Kit protocol. Starting with 100ng 
of total RNA, the Cy3-pCp (Cytidine bisphosphate) reagent was used to selectively 
label mature miRNAs according to manufacturer’s protocol. In combination with the 
miRNA microarray probe design, the Cy3-pCp (Cytidine bisphosphate) reagent 
ensures detection of both low-abundance and highly homologous miRNAs.  Each 
labeled sample was hybridized for 20 hours in a rotating hybridization oven.  Slides 
were washed and then scanned with an Agilent Scanner.  Data was obtained using 
the Agilent Feature Extraction software (v9.5), using the miRNA defaults for all 
parameters.  The Agilent Feature Extraction Software performed error modeling, 
adjusting for additive and multiplicative noise.  The resulting data were processed 
using the Rosetta Resolver® system (version 7.2) (Rosetta Biosoftware, Kirkland, 
WA). Error-weighted ratios and the associated p value were generated by Resolver 
to identify differentially expressed probes. The p-value p<0.05 was used to generate 
the gene lists.  
Quantitative PCR Analysis 
Total RNAs were isolated using the Ambion mirVana miRNA isolation kit (Austin, 
TX). For microRNA/small RNA analysis, total RNAs were reverse transcribed using 
the Taqman microRNA Reverse Transcription kit and analyzed using Taqman 
microRNA Assays (Applied Biosystems, CA, USA). All quantitative PCR reactions 
were performed on a 7900HT Real-Time PCR platform (Applied Biosystems, CA, 
USA).  
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Western Blotting and Antibodies 
Cells were harvested and lysed in 1X Laemelli Buffer containing 2.5% beta 
mercaptoethanol (BioRad, Hercules, CA). Whole cell lysates (20-30ug) were 
fractionated on 6% Tris-Glycine gels (Invitrogen) and transferred to nitrocellulose 
membranes. Membranes were probed overnight with the following antibodies: Dicer 
rabbit polyclonal, 1:200 (Santa Cruz Biotechnology, Santa Cruz, CA), beta-Actin, 
1:10,000 (Millipore, Billerica, MA). 
Dicer Depleted Cells 
CEM-C7 and Jurkat GRα cells were transduced with lentivirus encoding Dicer 
shRNA or non-targeting control at a multiplicity of infection of 5. Stable Dicer 
depleted cells were established by puromycin selection (2ug/mL). Anti-Dicer and 
non-targeting control Mission shRNAs were purchased from Sigma Aldrich USA.  
MiR-223 Overexpressing and Inhibited Cells 
CEM-C7 and Jurkat GRα cells were transduced with lentivirus encoding empty 
vector control, miR-223 pre-miRNA, or miR-233 antisense RNA at a multiplicity of 
infection of 20 and 50, respectively. Transduction at these multiplicity of infections 
resulted in a transduction efficiency of >90% as determined by CopGFP expression. 
Lenti-miR miR-223 precursor, miR-223 ZIP, and empty vector clones were 
purchased from System Biosciences (Mountain View, CA). 
Apoptosis Assays 
Apoptosis was evaluated via Annexin V/Propidium Iodide staining. For Annexin-V 
analysis, cells were stained with Annexin-V according to the manufacturer’s protocol 
and counterstained with propidium iodide (Trevigen, Gaithersburg, MD). Following 
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staining, cells were immediately analyzed on a Becton Dickinson FACSort cytometer 
equipped with CellQuest software. 
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3.8 FIGURES 
Figure 3.1 Primary thymocytes undergoing glucocorticoid-induced apoptosis 
or spontaneous apoptosis segregate into distinct cell-size sub-populations. 
Primary thymocytes were isolated and untreated or treated with 100nM 
dexamethasone for 6 hours. Apoptotic progression was monitored via flow 
cytometric analysis of cell size. Using control cells placed on ice (to stop the 
advance of apoptosis) as a template, a gating strategy was designed in order to 
segregate shrunken cells actively engaged in apoptosis from the whole cell 
population. Cells in red indicate non-shrunken, non-apoptotic cells and cells in green 
depict shrunken, apoptotic cells.  
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Figure 3.2 MicroRNA microarray analysis of apoptotic and viable sub-
populations demonstrates the prevalent repression of microRNA expression 
and the novel induction of microRNAs during both spontaneous and 
glucocorticoid-induced apoptosis of primary thymocytes. 
Sorted apoptotic and viable populations from primary thymocytes undergoing 
glucocorticoid-induced and spontaneous apoptosis were subjected to total RNA 
isolation and microRNA microarray analysis. (A) Analysis of microRNAs differentially 
expressed in glucocorticoid-induced and spontaneous apoptotic populations. Green 
indicates microRNAs significantly repressed during apoptosis and red indicates 
microRNAs significantly induced during apoptosis (four independent biological 
replicates, *p<. 05). Glucocorticoid-induced apoptosis occurs rapidly, requiring only 6 
hours to acquire 1x107 apoptotic cells while spontaneous apoptosis occurs slowly, 
requiring up to 12 hours of sorting to obtain 1x107 cells of the apoptotic population. It 
is likely that there were more microRNAs differentially regulated during spontaneous 
apoptosis due to the prolonged sorting duration in order to acquire 1x107 cells of the 
spontaneously apoptotic population. (B) Identification of microRNAs unique to 
glucocorticoid-induced or spontaneous apoptosis or shared by both programs. 
MicroRNAs present in the yellow region are specifically regulated during 
glucocorticoid-induced apoptosis, microRNAs present in the blue circle are 
specifically regulated during spontaneous apoptosis and microRNAs shared by both 
pathways are depicted in green.  
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Figure 3.3 Quantitative PCR analysis confirms the altered expression of 
microRNAs during glucocorticoid-induced and spontaneous apoptosis of 
primary thymocytes. Total RNAs obtained independently from those subjected to 
microarray analysis were analyzed by quantitative PCR for the validation of 
microRNAs induced and repressed during glucocorticoid-induced and spontaneous 
apoptosis. (A) Quantitative PCR confirmation of miR-451 and miR-223 induction in 
apoptotic populations of primary thymocytes undergoing both glucocorticoid-induced 
and spontaneous apoptosis. Results are expressed as percent of control mean 
values +/- SEM for four independent experiments (*p<. 05). (B) Quantitative PCR 
confirmation of let-7a, miR-15b, miR-17 repression in apoptotic populations of 
primary thymocytes undergoing both glucocorticoid-induced and spontaneous 
apoptosis. Results are expressed as percent of control mean values +/- SEM for four 
independent experiments (*p<. 05, **p<. 01). 
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Figure 3.4 The induction of miR-223 is refractory to Dicer loss during 
glucocorticoid-induced and spontaneous apoptosis. (A) Whole cell lysates from 
sorted viable and apoptotic populations undergoing glucocorticoid-induced or 
spontaneous apoptosis were immunoblotted with Dicer polyclonal antibody. Actin 
immunoblotting served as a loading control and results are representative of three 
independent experiments. (B) Stable silencing of Dicer protein expression in Jurkat 
GRα and CEM-C7 lymphocyte cell lines via lentiviral transduction of shRNA. Whole 
cell lysates from cells stably transduced with non-targeting control (NTC) or anti-
Dicer shRNA (Dicer KD) were immunoblotted with Dicer polyclonal antibody. Actin 
immunoblotting served as a loading control and results are representative of three 
independent experiments. Total RNAs from non-targeting control (NTC) and Dicer 
depleted cells (KD) were evaluated for the expression of miR-223 via quantitative 
PCR. The expression of Rnu43 small nuclear RNA served as an endogenous 
control. Results are reported as percent of non-targeting control values +/- SEM for 
three independent experiments (*p<. 05). 
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Figure 3.5 Inhibition of miR-223 enhances glucocorticoid-induced apoptosis in 
glucocorticoid-sensitive human lymphoid cell lines. The glucocorticoid-sensitive 
human leukemic cells lines Jurkat GRα and CEM-C7 were treated with 100nM 
dexamethasone for 24 and 48 hours. (A) Total RNAs from untreated and 
dexamethasone-treated cells were evaluated for the expression of miR-223 via 
quantitative PCR. The expression of Rnu43 small nuclear RNA served as an 
endogenous control. Results are reported as percent of non-targeting control values 
+/- SEM for three independent experiments (*p<.05). (B) Efficient overexpression 
and inhibition of miR-223 via lentiviral transduction. Jurkat GRα and CEM-C7 cells 
were stably transduced with lentivirus encoding empty vector control, miR-223, and 
miR-223 anti-sense RNA (miR-223 ZIP). The expression of miR-223 was evaluated 
via quantitative PCR. The expression of Rnu43 small nuclear RNA served as an 
endogenous control. Results are represented as mean percent of vector control 
values +/- SEM for three independent experiments. (C) Jurkat GRα and CEM-C7 
cells stably expressing empty vector control, miR-223, or miR-223 anti-sense RNA 
(223-ZIP) were treated with 100nM dexamethasone and apoptosis progression was 
monitored was monitored by flow cytometric analysis of Annexin-FITC/propidium 
iodide staining. Results were normalized to untreated control and values are 
representative of six independent experiments (*p<.01). 
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Supplementary Figure 3.1 Stable and efficient overexpression of miR-223-
targeting anti-sense RNA. The expression of miR-223-specific antisense RNA 
(223-ZIP) in Jurkat GRα and CEM-C7 cells was confirmed by quantitative PCR 
analysis using a custom small RNA primer/probe. Results are normalized to Rnu43 
and expressed as % of control +/- SEM for three independent experiments.  
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CHAPTER 4 
 
 
 
GENERAL DISCUSSION
4.1 DISCUSSION 
Apoptosis of lymphocytes is critical for the homeostatic balance of the 
immune system. The escape of lymphocytes from apoptotic constraint can lead to 
dire consequences including the development of hematomalignancy and 
autoimmune disorders. Endogenous glucocorticoids are critical regulators of immune 
development through the execution of unwanted immature thymocytes during the T-
cell selection process (1). Furthermore, the glucocorticoid receptor serves as a 
sensor of environmental stress and endogenous glucocorticoids influence the 
response of the immune system to environmental stress and toxic insult. Given their 
aggressive pro-apoptotic properties, synthetic glucocorticoids are a mainstay of 
hematomalignant chemotherapeutic regimens. The changes in gene expression that 
contribute to the progression of glucocorticoid-induced apoptosis have generated 
considerable interest among the glucocorticoid research community. Numerous 
laboratories have performed genome-wide microarray analysis to identify messenger 
RNAs differentially expressed during glucocorticoid-induced apoptosis (2-8). 
However, to date, the identification of non-coding microRNAs differentially 
expressed during (and perhaps contributing to) the progression of glucocorticoid-
induced apoptosis remains unaddressed. Recently, microRNAs have emerged as 
important regulators of lymphocyte function and survival through both the induction 
and antagonism of apoptosis (9). The research presented in this dissertation 
describes the altered regulation of microRNA expression during glucocorticoid-
induced apoptosis of primary thymocytes and further elucidates the contribution of 
this altered regulation to the progression of glucocorticoid-induced apoptosis. 
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 Our analysis of the microRNAnome during glucocorticoid-induced apoptosis 
of primary thymocytes demonstrated prevalent downregulation of microRNA 
expression. This downregulation was correlated with the dysregulated expression of 
the microRNA bioprocessors Drosha, DGCR8, and Dicer. We further demonstrated 
that the stable depletion of Dicer expression (and the subsequent mature microRNA 
repression) in two glucocorticoid-sensitive human leukemic cell lines enhanced the 
progression of glucocorticoid-induced apoptosis. Interestingly, the stable 
overexpression of Dicer in these cell lines blunted the progression of glucocorticoid-
induced apoptosis. However, these results are difficult to interpret as Dicer 
overexpression resulted in decreased glucocorticoid receptor (GR) protein 
expression, perhaps accounting for the attenuation of glucocorticoid-induced 
apoptosis in these cells. This decreased GR expression occurs post-
transcriptionally, possibly through the Dicer-dependent induction of GR-targeting 
microRNAs, however this particular hypothesis requires further investigation. Finally, 
the contribution of specific microRNAs repressed during glucocorticoid-induced 
apoptosis was examined via the stable overexpression of the miR-17-92 polycistron 
members. Overexpression of this polycistron in-vitro and in-vivo blunted 
glucocorticoid induced apoptosis of lymphocytes, suggesting that the specific 
repression of miR-17-92 polycistron members contributes to the cell death process. 
Importantly, members of this polycistron have been reported to target an important 
pro-apoptotic component of the glucocorticoid-induced signaling cascade, Bim, in-
vivo (10-14). Therefore, it is possible that ablated Bim expression under conditions 
of miR-17-92 upregulation may account for the diminished glucocorticoid-induced 
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apoptosis of both cultured leukemic and primary thymocytes. Currently, this specific 
hypothesis is under further investigation.  
Historically, the analysis of altered gene expression during glucocorticoid-
induced apoptosis of primary thymocytes has been complicated by the stochastic 
kinetics of this apoptotic program (15). Gene expression analysis of heterogeneous 
apoptotic populations likely underestimates or overlooks completely the changes in 
gene expression occurring during glucocorticoid-induced apoptosis. Here, we 
describe the development of a novel, size-based cell sorting strategy to narrow 
microRNA expression analysis to only those cells displaying the morphological 
characteristics of apoptosis. Analysis of these apoptotic primary thymocyte sub-
populations confirmed our previous observation of prevalent microRNA repression 
during glucocorticoid-induced apoptosis, as well as spontaneous apoptosis, and also 
revealed the induction of a subset of microRNAs in both apoptotic pathways. These 
microRNAs (miR-223 and miR-451) were induced under conditions of Dicer 
depletion during both apoptotic programs and the stable silencing of Dicer in two 
glucocorticoid-sensitive human leukemic cell lines significantly enhanced the 
expression of the induced microRNA, miR-223. The recent discovery of a Dicer-
independent, Argonaute-2 (Ago2) dependent microRNA bioprocessing pathway 
implies that our Dicer-independent induced microRNAs may be processed via the 
Ago2 dependent pathway (16). Expression analysis of these induced microRNAs 
under conditions of Ago2 depletion in-vitro and in-vivo would illuminate the 
mechanism of microRNA induction in Dicer-depleted apoptotic sub-populations. 
Gain and loss-of-function studies examining the role of miR-223 induction in 
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glucocorticoid-induced apoptosis indicate that in glucocorticoid-sensitive leukemic 
cells, miR-223 is an anti-apoptotic effector. However, to fully delineate the role of 
miR-223 induction in the progression of glucocorticoid-induced immature thymocyte 
apoptosis, we propose the development of a lymphocyte-specific miR-223-deficient 
mouse. The development of this mouse model would generate a potentially 
intriguing avenue for the future study of microRNA modulation of glucocorticoid-
induced apoptosis.  
 Since their initial discovery, microRNA research has expanded exponentially, 
identifying a myriad of diverse roles for these small molecules. Recently, microRNAs 
have emerged as effective biomarkers of disease and toxic injury. Altered tissue 
microRNA expression has been described for numerous cancers and tissue-derived 
microRNAs have been successfully utilized in the profiling and diagnosis of cancers 
(17). The use of microRNA biomarkers has rapidly accelerated since the discovery 
of stably circulating serum microRNAs. These microRNAs have been validated as 
minimally invasive, effective serum biomarkers of breast (18), colorectal (19), 
prostate (20), central nervous system (21), esophageal (22), and gastrointestinal 
(23) cancers as well as non-malignant neurodegenerative (24) and rheumatic (25)  
diseases, myocardial infarction (26), and drug-induced liver injury (27).  
 Interestingly, the prevalent dysregulation of microRNA expression in cancer 
may also contribute chemotherapy resistance. For example, miR-451 is 
downregulated in doxorubicin-resistant MCF-7 breast cancer cells, resulting in the 
increased expression of Multi-Drug Resistance 1 (MDR1) (28). Ectopic 
overexpression of miR-451 downregulated MDR1 expression and restored 
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doxorubicin sensitivity to these cells (28). Synthetic glucocorticoids are a 
cornerstone of hematomalignant chemotherapy regimens and their efficacy is 
severely limited by the development of glucocorticoid-resistance. MicroRNAnome 
profiling of a glucocorticoid-resistant ALL cell line reported the downregulation of 
miR-128b and miR-221 (29). Simultaneous overexpression of these two microRNAs 
restored glucocorticoid-sensitivity to these cells through a GR-independent 
mechanism (29). The overexpression of microRNAs targeting GR in glucocorticoid-
resistant hematomalignancies may be an alternative mechanism of acquired 
glucocorticoid-resistance, however to date, this hypothesis remains unexamined.  
 MicroRNAs are also promising therapeutic targets. The first microRNA-
targeting drug, antimiRTM-122, antagonizes liver-specific miR-122 and represses 
hepatitis C viremia in non-human primates (30). This encouraging new drug recently 
entered phase II clinical trials (31).  Given the success of this initial offering, the 
modulation of microRNA function via antagonism or delivery microRNA mimetics has 
captured the interest of the pharmaceutical and toxicological research communities. 
However, the identification of microRNAs contributing to pathogenesis and the 
evaluation of microRNAs suitable for therapeutic targeting requires a basic 
understanding of the mechanisms regulating microRNA expression and function. 
This dissertation establishes a fundamental understanding of microRNA expression 
under conditions of glucocorticoid-induced lymphocyte apoptosis and further 
delineates the functional significance of this apoptotic microRNA signature.  
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